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ABSTRACT (Summary) 
 
Background: Increasing attention has been paid to preventative health over the past few decades. 
However because of constraints on consultation time and medical funds general practitioners (GPs) are often 
unsure which measures are appropriate and when to carry them out. They need to be well informed about the 
cost-effectiveness and evidence regarding each preventative measure to help their patients make informed 
choices about what needs to be done.  Due to the large number of recommended screening measures general 
practitioners are often unsure which to prioritise and also forget to carry out all recommended measures. 
Recommendations for screening in South Africa and research into preventive strategies used by general 
practitioners are lacking. This research attempts to find out whether the prevention strategies used by general 
practitioners in private practice in Grahamstown follow recommended guidelines.  
 
Methods: To obtain a broad understanding of prevention strategies used by general practitioners in 
Grahamstown, the following tracer conditions were selected for the study: screening for smoking, breast 
cancer, cervical cancer, colorectal cancer, hyperlipidaemia, prostate cancer and human immunodeficiency 
virus (HIV) infection. Research on routine annual health checks was included as these are used by many GPs 
to screen for tracer conditions. The research was done in 2 parts: 1. Review of the literature to obtain 
evidence on the recommended prevention strategy for each of the selected tracer conditions and 2. Interviews 
with GPs to evaluate the prevention strategy they used for each tracer condition. The literature was reviewed 
for evidence on the following parameters for each tracer condition:  burden of the disease prevented; cost-
effectiveness of the screening measures; sensitivity and specificity of screening tests; whether the screening 
measure for and treatment of the tracer condition is acceptable to patients; appropriate duration between 
repeated screening tests and whether there is effective treatment for the tracer condition. Eleven general 
practitioners were interviewed on the prevention strategies they use for each of the selected tracer conditions. 
Transcriptions of the interviews were analysed qualitatively and qualitatively. The prevention strategies used 
by the general practitioners was then compared to recommended guidelines.  
 
Results: Evidence from the literature regarding the burden of and optimal prevention strategy for each 
tracer condition is reported. Using this evidence an appropriate prevention strategy for each tracer condition 
is outlined. The prevention strategies used by the GPs for each tracer condition and the routine annual health 
check is reported from the analysis of the interviews. The results show a wide range of differing strategies 
used by the GPs, often not following recommendations from research. 
 
Discussion: The prevention strategies used by general practitioners for each tracer condition is compared 
with the recommendations from the literature. Important differences between what are recommended and 
what general practitioners are doing is discussed. Some general practitioners are practicing largely curative 
medicine and are not adequately screening their patients. Others are over screening with too many 
unnecessary tests being done annually as a routine. The interviews reveal that generally GPs do not discuss 
the potential harms and limitations of screening tests with their patients; do not keep check lists for each 
patient and do not use registers or recall systems to ensure all screening is done. 
 
Conclusion: General practitioners need to ensure their prevention strategies follow recommended 
guidelines. To do so they can use the routine annual health check or opportunistic case finding and 
prevention. They need to ensure that routine health checks are targeted to the individual patients’ health risks 
and avoid doing unnecessary tests. Check lists can help to ensure all screening is done on every patient. 
While registers and recall systems improve screening rates they are not always possible in busy general 
practices. Recommended prevention strategies for each of the tracer conditions are made. 
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INTRODUCTION 
 
Traditionally the main role of general practitioners (GPs) has been to treat illness. However internationally 
there has been increasing attention paid to prevention strategies over the past few decades. This has resulted 
in an ever increasing number of recommended screening preventative measures for family physicians to 
include in their consultations. In the private sector the increasing number of patients on managed care and 
other pressures to see patients as quickly as possible means there is pressure on GPs to spend less time on 
preventative measures to promote health. With constraints on consultation time and medical funds it is 
difficult to be sure which measures are appropriate and when to carry them out. GPs need to be well 
informed about each preventive measure and help their patients make informed choices about which need to 
be done. Preventive measures are an important part of primary health care but as health spending has become 
such an important issue, screening needs to be cost-effective and evidence based.   
 
Research shows that half of the deaths due to heart disease, cancer, stroke and chronic obstructive pulmonary 
disease are potentially preventable with simple measures like stopping smoking, diet and exercise.
1
 Patients 
are reluctant to heed advice to live healthy lifestyles and patient education is the most poorly carried out 
function by doctors. Disadvantaged communities tend to be given preventive services at an even lower rate.   
 
General practitioners need to be well informed about each screening test to ensure they can advise their 
patients appropriately. Ideally screening tests should be highly sensitive and specific. Those at risk must be 
willing to take part in the screening measure and find the treatment of the condition acceptable. Screening 
intervals must be shorter than it takes for the illness to become untreatable and early treatment must be 
effective. Practitioners must also be aware of the advantages and disadvantages of screening. Advantages 
include better prognosis and easier treatment of cases detected early and reassurance for patients with 
negative results. Disadvantages can be a longer period of morbidity if the prognosis is unaltered, unnecessary 
treatment of doubtful or false positive results, false reassurance for those with false negative results and 
increased stress with false positive results. Doctors must explain these advantages and disadvantages and any 
other risks or implications before recommending a screening measure.     
  
Because doctors were unsure which screening tests to recommend, the Canadians set up a task force in the 
1970’s to research guidelines for preventive measures in clinical practice.2 Reviewing medical evidence they 
identified conditions and risk factors that were most suitable for preventive measures. The Americans 
followed suit with the United States Preventive Services Task Force (USPSTF).
3 
This task force continues to 
report on scientific evidence and makes recommendations regarding preventive measures. General 
recommendations regarding screening they have made are: 
 
1. Interventions should focus on each patient’s particular health practices. 
2. Patients should be involved in making decisions about screening. 
3. There must be evidence that preventive measures being used are effective. 
4. Doctors should try and discuss prevention at every consultation with their patients. 
5. Some preventive measures are best dealt with at a community level rather than by individual doctors.
3
 
 
The USPSTF has made recommendations on an extremely large number of preventive measures such that 
GPs are unsure which measures to prioritise. Ashley and Coffield did an interesting assessment of 30 clinical 
preventive services recommended by the USPSTF. They valued the services based on the burden of the 
disease prevented and cost-effectiveness of the service and then put them in ranking order. To prioritise 
which services needed improved delivery they compared the ranking with known delivery rates. They found 
several preventive measures with a high ranking but low delivery rate.
4 
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Smith and Herbert assessed the practice of preventive measures by GPs in British Columbia compared to 
Canadian Task Force recommendations. They sent a questionnaire to 300 GPs asking about preventive 
measures for 4 common cancers-cervix, breast, lung and colon. They found that the GPs did not follow 
recommendations properly; they tended to comply with traditional measures recommended but also persisted 
with traditional measures no longer recommended and did not adopt new recommendations.
5
 A study using 
practice nurses to record the delivery of preventive services by family physicians showed a wide variety of 
delivery rates during routine health visits and low rates during visits for illness. Only 55% of screening 
measures and 9% of counselling for unhealthy habits were up to date.
6 
 
Apart from being unsure which measures to recommend doctors often forget to carry them out. Dubey and 
Glazier developed preventive guidelines for adult care in the form of checklists (one for females and one for 
males) for family physicians in Canada. They researched evidence on recommended preventive measures and 
drew up checklists of those which are practical for family physicians to carry out. Some of the measures are 
not evidence based but are carried out routinely in practice. They claim the forms are cost effective and easy 
to use.
7
 In a randomized controlled trial to assess their effectiveness it was found that carrying out preventive 
measures by family physicians improved with the use of these checklists.
8
  
 
There are many barriers to practitioners carrying out screening and prevention. Reviewing literature Wender 
tried to identify what these barriers are. He found 3 types of obstacles: practitioner-specific, patient-specific 
and health system barriers. Practitioner-specific obstacles he found were lack of time, competition with other 
health needs, disagreement with recommendations and lack of expertise. Patient-specific obstacles were 
refusal to test and insufficient funds. Health system obstacles were inadequate insurance, space or staff. He 
concludes that to improve screening practitioners must be helped to identify and overcome barriers.
9
  
 
Yarnall et al researched the time required for a GP to carry out recommended preventive services on an 
average number of patients seen each day. They found a doctor would need 1773 hours a year (7.4 hours per 
day) to provide all the services graded A or B recommended by the USPSTF.
10
 Pimlott points out that “the 
number of recommended prevention strategies grows each passing year making it increasingly difficult for 
family physicians to find time to implement them”. He notes that these recommendations come from various 
interest groups and do not always have good evidence to support their use. He also found that the media 
increased public demand for some screening measures and that family physicians are faced with spending a 
great deal of time trying to explain the evidence regarding screening measures or doing what the patients 
demand to save time. Pimlott states that preventive measures need to be prioritised so family physicians 
know how much time to spend on each and that the public must be involved in deciding how these should be 
carried out. He goes on to question whether doing prevention when patients have visited for another illness 
should still be recommended and is even ethical.
11
  
 
There is not much research on recommended preventive measures for South Africa or on the preventive 
strategies used by GPs in South Africa. This research attempts to find out whether the prevention strategies 
used by general practitioners in private practice are appropriate and follow recommended guidelines. As 
there are no specific protocols or guidelines for screening in general practice in South Africa, it is possible 
that screening strategies used by GPs vary a great deal and often do not follow what is recommended.    
 
The aim of this study was to evaluate the prevention strategies used by general practitioners in Grahamstown 
in terms of the recommended guidelines for selected tracer conditions. In this study prevention strategies 
used by GPs for each tracer condition means what screening tests or measures they use; what age they 
recommend their patients do the screening tests; how often these are repeated; when they carry out screening 
(opportunistically or on a routine basis during routine annual health checks for instance); whether patients are 
informed about the advantages, benefits, disadvantages and harms of each screening measure and whether 
Stellenbosch University  https://scholar.sun.ac.za
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they use check lists or registers as reminders to ensure all patients are screened appropriately. This study, 
unless otherwise stated, refers to screening or prevention strategies only on normal healthy people without 
risk factors for or symptoms of the tracer condition. Prevention strategies for this study means the screening 
measures used to detect the tracer condition. Where interventions are an integral part of the screening 
process, for instance smoking cessation advice when screening for smoking, these have also been researched 
as part of the prevention strategy.    
 
Grahamstown is a small town in the Eastern Cape with a population of approximately 175 000 people. There 
are 16 private general practitioners working in Grahamstown. The practice profile of two of the GPs is 
largely disadvantaged poor patients whereas all the other GPs attend to a wide spectrum of the community 
from the very poor to the wealthy. 
 
The objectives of the study were to: 
1. Select appropriate tracer conditions for general practice in Grahamstown and research the literature 
for recommended prevention strategies for these conditions. 
2. Get a broad understanding of the prevention strategies used by GPs in Grahamstown for these tracer 
conditions. 
3. Compare the prevention strategies used by the GPs with recommended guidelines. 
4. Make recommendations for appropriate screening in general practice in Grahamstown. 
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METHODS 
 
The following tracer conditions were selected for this study: 
 Screening for smoking 
 Screening for breast cancer 
 Screening for cervical cancer 
 Screening for colorectal cancer 
 Screening for hyperlipidaemia 
 Screening for prostate cancer 
 Screening for human immunodeficiency virus (HIV) infection 
These conditions were chosen as a review of the literature showed them to be important common conditions 
that should be screened for in adults in general practice. Because of limitations to the size of the research and 
the length of interviews with general practitioners more tracer conditions could not be included. Fewer tracer 
conditions researched in more depth would not have given a broad understanding of the screening strategies 
used by GPs. The choice of these tracer conditions was discussed with two GPs in private practice in 
Grahamstown and both agreed these conditions should be screened for routinely and screening measures for 
these are well known in general practice. They suggested that research on routine annual health checks be 
included as these are used by many general practitioners to screen for all of these tracer conditions on an 
annual basis. This would give a good general overview of the prevention strategies used by GPs to screen for 
all tracer conditions.     
 
The research was done in 2 parts: 1. Review of the literature to obtain evidence on the recommended 
prevention strategy for each of the selected tracer conditions and 2. Interviews with GPs to evaluate the 
prevention strategy they used for each tracer condition.  
 
1. Literature review 
Research of the literature was conducted to determine recommended prevention strategies for each of these 
tracer conditions. A large number of studies; mainly randomized controlled trials, systematic reviews, meta-
analyses and task group reports were used to find reliable evidence. While researching the literature evidence 
on some of the following parameters, based on the World Health Organisation’s criteria for disease 
screening
14
,
 
were looked for: 
 The burden of the disease prevented. 
 The cost-effectiveness of the preventive measure. 
 The sensitivity and specificity of screening tests. 
 Whether patients will find the preventive measure and treatment of the tracer condition acceptable. 
 The appropriate duration between repeated screening tests. 
 Whether there is effective treatment for the tracer condition. 
 
2. Interviews with general practitioners 
Interviews using structured questionnaires were carried out  with GPs in Grahamstown to evaluate the 
prevention strategies they use for the selected tracer conditions and routine annual health checks. They were 
asked whether they recommended routine annual health checks and used these to screen for tracer conditions. 
They were then asked about different aspects of the routine annual health check and prevention strategies for 
each of the tracer conditions selected. The interviews were piloted on two general practitioners. These pilot 
interviews revealed that generally the questions were appropriate to evaluate the prevention strategies used 
by GPs. The respondents of the pilot interviews gave positive feedback and did not feel the interviews 
needed changing much. However they did comment that the interviews were a bit long and they were getting 
tired towards the end. Therefore the number of questions on each preventative measure was reduced. (See 
Addendum 1 for structured questionnaire used for the interviews with GPs). Repetition was avoided in the 
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interviews by recognising patterns of screening and not repeating similar questions about the different 
screening measures. GPs were asked what their prevention strategy was for each tracer condition and if they 
gave a comprehensive answer were then not asked specific questions about each detail of their screening 
strategy. A few general questions were asked at the end of each interview to get an overview of each GP’s 
approach to screening 
.  
The study population was the private general practitioners in Grahamstown. Those GPs involved in selecting 
tracer conditions and piloting the interviews were not included. As many of the rest of the GPs in 
Grahamstown who were prepared to take part, were included to make the results as representative as 
possible. There were no exclusion criteria. As basic principles apply to all general practices and the patient 
demographics of the GPs in Grahamstown include a wide spectrum of patients the study population was 
chosen as a possible representative sample of private general practice in South Africa. It is possible that the 
results are relevant to GPs in private practice throughout South Africa because strategies used by the study 
population reflect those used by many others in the country.  
 
Thirteen GPs were contacted telephonically to request an interview. Eleven of them obliged immediately and 
arranged a time for the interview. Two GPs said they would arrange a time for an interview but never did. All 
the GPs who agreed to an interview did not mind being recorded. Six of the GPs practice together, 3 are solo 
general practitioners and 2 are from a small group practice. Two of the GPs serve poor communities and the 
rest serve a broad cross section of the community. The six from the same practice did not have very similar 
prevention strategies. The only screening measure which they practiced similarly was doing annual PAP 
smears because they had all been advised by the same gynaecologist to do so. The 11 GPs were given 
information leaflets and consent forms (Addendum 2) to read and sign before the interview.  
 
Each interview took between 30 to 45 minutes. The GPs all showed signs of getting bored or tired by the end 
of the interview. One interview was interrupted near the end as the GP was called to an emergency and was 
unable to complete the interview. The GPs were all very open and relaxed and soon after starting the 
interviews seemed to forget they were being recorded. None of the GPs seemed to feel they were being 
assessed about how much they knew and were quite happy to acknowledge they did not know about 
something when this was the case. They all seemed to give an honest account of what they actually do in 
practice. Some were interested in and asked about recommendations they felt unsure about. An attempt was 
made by the researcher not to ask questions in such a way that indicated to the GPs how things should be 
done. All the GPs gave their opinions openly and did not seem inhibited in the interviews. Because the 
researcher was a GP interviewing other GPs sometimes the respondent would not answer the question 
completely because he/she felt the researcher had an understanding of what was being meant. This may have 
lead to some information being missed.  
 
During the interviews patterns of practice or opinion were looked for and then checked for in subsequent 
interviews. The interviews were transcribed anonymously by a typist from the recordings. The transcribed 
data was analysed qualitatively by grouping information from each of the interviews on the different tracer 
conditions together. This data was analysed on the prevention strategy used and the views of the GPs 
regarding screening for each tracer condition. Themes or similar strategies and opinions on each condition 
were looked for like whether GPs used routine annual health checks or opportunistic case finding as a general 
prevention strategy; whether they used check lists or registers and if they found it necessary to explain the 
potential benefits and harms of screening tests to patients. The response from each GP was then compared 
with all the other responses.  An attempt was made to determine why certain strategies are used. Interesting 
comments or opinions from the GPs which revealed why they do things in a certain way was looked for. 
While this was largely a qualitative study some of the data from the interviews required quantitative analysis 
like the number of GPs using the same preventive strategy for a tracer condition.  
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Ethically the researcher needed to ensure privacy of the information given by the general practitioners. This 
was done by recording the interviews privately, not attaching names to the recordings and ensuring that the 
data was transcribed and analysed anonymously. The recordings were destroyed after transcription and no 
names are mentioned in the research report. Informed consent was obtained from the GPs to conduct 
interviews. An explanation was given to participants why the research was being done and how the 
interviews would be conducted. It was pointed out that if they felt uncomfortable they were free to withdraw 
from the research at any stage. The research was passed by the ethics committee at the University of 
Stellenbosch. 
 
The strength of this study was to research good quality evidence for recommendations on screening strategies 
for each selected tracer conditions. This makes the data reliable and valid. However as several tracer 
conditions were included in the study the depth of information and debate regarding recommended 
prevention strategies for each was limited. Instead of an in depth analysis of screening strategies for one or 
two tracer conditions the study provides a broader overview of prevention strategies in general practice. 
Including research on interventions for some of the tracer conditions makes the study less focussed but also 
leads to a broader understanding of prevention strategies used by GPs. 
  
Reliability of the information given by the GPs during the interviews may have been affected by the fact that 
the researcher’s relationship with each GP is different and that some of the GPs may have felt their work was 
being assessed and therefore give answers that they think are correct rather than what they actually do in 
practice. However these problems did not occur significantly as the GPs all answered questions very openly 
and honestly resulting in reliable data. Limitations on time available to GPs for interviews and the large 
number of tracer conditions included in the study resulted in limitations on the amount of information 
obtained from the interviews.  
 
As the researcher is a general practitioner in the same working environment as the GPs being studied the 
validity of answers given during interviews was easily assessed. Validity of the study results is also improved 
by clearly describing how it was collected and analysing the transcribed words of those interviewed. Direct 
quotes are reported, where appropriate, to express the opinions of GPs accurately. However the validity of 
the data is limited by the fact that only one researcher analysed the data and triangulation was not done.  
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RESULTS 
 
The findings of the literature review on recommended prevention strategies and the results obtained from the 
interviews with GPs on their prevention strategies will be reported for each tracer condition in turn.  
 
Routine annual health check  
 
a) Literature review: Recommendations on the routine annual health check 
 
There is controversy in the literature regarding the value of routine physical examinations on healthy people. 
Some feel routine health examinations should be targeted to the specific risks of each individual. Prochazka 
et al found, in a survey of 783 primary care physicians, 88% perform routine examinations. Most of the 
clinicians (74%) felt the routine health check detected sub-clinical illness although evidence does not support 
this. Many included screening tests as a routine in these medical check ups despite there being no evidence to 
support doing these tests annually as a routine. Most found the annual physical examination gave them time 
to discuss preventive health issues (94%) and improved their relationship (94%) with their patients. They 
(78%) also felt that most patients wanted the examination.
12
 In a systematic review of the value of the routine 
annual health check it was found that this increased the delivery of gynaecological examinations, PAP 
smears, cholesterol testing and faecal occult blood tests
13
. It also showed that routine health checks reduce 
patient worry about illness. However the researchers state that more research is needed to assess the long 
term benefits, harms and cost effectiveness of routine health checks
13
. 
 
Recommendations: From the literature it is difficult to recommend whether GPs should do routine annual 
health checks or not. However it is a useful examination to ensure all necessary screening is done and 
patients generally want them to be done. Prevention needs to be done opportunistically and by case finding if 
GPs decide not to do routine annual health checks. 
 
b) Interview results: Strategies used by GPs in Grahamstown regarding the routine annual check up 
 
Analysis of the responses from the interviews shows that some GPs do not recommend routine annual check 
ups to their patients. The reasons for not doing this seem to vary. Some practice mainly curative medicine 
and acknowledge they do not focus much on preventative care while others do not believe there is value in 
the routine annual check up. One GP said he felt the routine health check was not a “directed approach to 
solving problems” and he preferred a more directed or targeted approach to helping patients. He also felt 
there is “low pick up” of disease with these routine health checks. The GPs who do not recommend routine 
health check ups seem to do their screening in a targeted way by recommending tests to patients with specific 
risks or when they have symptoms associated with a tracer condition. For example recommending PAP 
smears to women when they present with gynaecological symptoms. Those GPs who do not recommend 
routine annual check ups do them if the patient requests it. None of the GPs dissuaded their patients or 
refused to do annual check ups. One of the GPs had many requests for annual checks ups although she did 
not believe these were valuable. The reasons for doing the routine health check although they did not 
recommend it varied. One felt it was the “patient’s right to know they are healthy” and that he would do it to 
“reassure the patient”.  One GP gave the following reason: “I would do it because patients in private 
practice would not understand if you said no and think you are being a bad doctor. So I do it for public 
relations really, not for health benefits”.  
 
Six of the 11 GPs interviewed strongly recommended annual health check ups. The age they recommend 
patients start these check ups vary. Most start screening women at about age 20 or from when they become 
sexually active because they need PAP smears. Most recommend routine health checks begin on men over 
the age of 40 years. None of the GPs have a register or recall system. The patients are left to remember to 
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return for their annual check up. Some recommend to their patient they come in the month of their birthday 
as a way of remembering to have it done. The GPs who do recommend annual check ups feel there is value 
beyond picking up tracer conditions. They feel it is an opportunity when the patient focuses on their health 
and lifestyle; it is an opportunity to discuss prevention; it gives the doctor the opportunity to get to know 
their patient better and improves the doctor patient relationship. The GPs who recommend annual check ups 
tend to have a standard screening strategy rather than focusing on the individuals particular health practices. 
They include a wide range of tests in these annual check ups. Most do urine testing, ECG, urea and 
electrolytes, full blood count, glucose, lipogram and PSA in men and Pap smear and breast examination in 
women. Some include liver function tests, thyroid tests, rectal examinations on men and vaginal 
examinations on women in these annual check ups. Most of those GPs who recommend annual health checks 
say they have picked up medical conditions like high cholesterol and cancer of the prostate. Others feel they 
pick up very little pathology but do the annual check up because of the other benefits described above. Many 
of the GPs who do routine annual checks book their patients for a prolonged consultation for these to give 
them time to address all appropriate prevention issues. One GP stated he found the annual check allows him 
“to get a good feeling for where his patient is health wise and mood wise without necessarily picking up any 
aberrant pathology”. Every GP seems to have a group of patients who demand routine annual checks. GPs 
do not involve their patients in discussions about the potential benefits and harms of these check ups, instead 
they get on and do them. All the GPs noted that routine annual check ups are done infrequently amongst their 
more disadvantaged patients.   
  
Screening for smoking 
 
a) Literature review: Recommendations on screening for smoking 
 
Screening for tobacco use and encouraging patients to stop smoking is primary prevention to prevent diseases 
like stroke, heart and lung disease. In those patients who already have these conditions it may be considered 
part of tertiary prevention to prevent further deterioration.  
 
Smoking is a serious public health problem increasing the risk of many diseases and thus the burden of 
disease justifies screening. There are an estimated 1.2 billion smokers worldwide, of which half will die 
prematurely of a disease caused by their smoking, losing on average 8 years of their lives
15
. It is especially 
important in South Africa because, although smoking is on the decline in developed countries it is increasing 
rapidly in low and middle income countries, especially among disadvantaged groups
15
. The South African 
Comparative Risk Assessment Collaborating Group estimated the burden of disease due to smoking in South 
Africa in 2000. They found that smoking caused between 41 632 and 46 656 deaths (8-9% of deaths) and 
3.7-4.3% of disability adjusted life years in 2000
16
. Smoking was the third highest risk factor for mortality 
after unsafe sex and high blood pressure. Three times as many males as females died from smoking. They 
conclude that smoking causes a large burden of preventable disease in South Africa and should be a major 
public health priority
16
. 
 
Diseases associated with smoking are numerous. The strongest associations are with lung and heart disease, 
especially lung cancers, chronic obstructive pulmonary disease and ischemic heart disease
15
. The onset of 
these diseases usually occurs after many years of smoking and therefore there is a long pre-symptomatic 
phase which provides an opportunity for intervention. General practitioners have different beliefs about the 
effectiveness of smoking cessation interventions. Many general practitioners have negative beliefs and 
attitudes towards smoking cessation interventions like they are too time consuming and ineffective
17
. Many 
do not feel confident in their ability to discuss smoking with their patients or find such discussions 
unpleasant
17
. Other barriers to general practitioners getting involved in smoking cessation are concerns about 
patients being too sensitive about discussing smoking and feeling patients lacked motivation to stop 
smoking
18
. GPs often use ineffective strategies regarding smoking cessation and fail to identify smokers. 
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General practitioners are more likely to give smoking cessation advice when the patient presents with a 
smoking related problem
18
.  
 
Screening for smoking and counselling to stop smoking is cost effective and the benefits outweigh the harms. 
There is good evidence that advice from GPs to patients to stop smoking is effective. A Cochrane Review of 
39 trials on the effect of doctors’ advice to stop smoking showed a significant increase in the odds ratio of 
patients quitting for at least 6 months
19
. They found evidence that giving intensive advice had a small 
advantage over less intensive advice. However the US Clinical Practice Guidelines review showed 
incremental effect with increasing intensity advice
3
. Counselling lasting less than 3 minutes had an 
abstinence rate of 13.4% compared to counselling lasting more than 10 minutes with an abstinence rate of 
22.1%. Increasing the number of treatment sessions improved abstinence rates.
3
. The United States 
Preventative Services Task Force (USPSTF) found good evidence that interventions to stop smoking like 
screening, motivational interviewing and medication are effective in reducing the number of smokers and 
those who remain off smoking after 1 year
3
. Importantly they found good evidence that stopping smoking 
lowers the risk of heart disease, stroke and lung disease. The risk of death from smoking falls soon after 
stopping
17
. The reduction of risk differs for the different diseases but is significant. For instance the risk of 
lung cancer drops to 50% after stopping smoking for 10 years
17
.  
 
GPs should use evidence based approaches when implementing smoking cessation strategies. There is 
evidence that using the 5 ‘As’ strategy is effective in increasing quit rates amongst smokers. These 5 ‘As’ 
are: 1. Ask and identify the smoker. 2. Advise all smokers to quit. 3. Assess willingness to quit. 4. Assist the 
patient to quit. 5. Arrange follow up contact
17
. The Smoking Cessation Guidelines for Australian general 
practice use the 5 ‘As’ framework together with the stage of change assessment and motivational 
interviewing
20
. GPs can offer nicotine replacement therapy or bupropion after motivational interviewing to 
those who want it. A Cochrane review on nicotine replacement therapy showed that it can nearly double the 
number of patients who stop smoking compared to using no medication
21
. Thus nicotine replacement therapy 
increases the chance of stopping smoking and is most effective when combined with counselling
21
. There is 
evidence that bupropion is as effective as nicotine replacement therapy when given with intensive 
behavioural support
22
. About 19% of smokers who use bupropion to stop smoking achieve long term 
abstinence. The effectiveness of bupropion has only been tested with intensive behavioural support
22
.  
 
Recommendations: A review of the literature shows that as the burden of disease from smoking is high and 
smoking cessation advice effective screening for smoking is recommended. The recommended strategy is to 
screen all potential smokers and use evidence based approaches to counsel those who smoke. GPs should 
carry out a number of treatment sessions to improve abstinence rates and consider offering nicotine 
replacement therapy or bupropion. 
 
b) Interview results: Strategies used by GPs in Grahamstown to screen for smoking 
   
All the GPs interviewed screened for smoking but the strategies they use varies. There are three types of 
strategy they use:  
1. those who only ask about smoking if the patient presents with a smoking related symptom or illness;  
2. those who find out if the patient smokes at their first consultation as part of the history and  
3. those who regularly ask their patients whether they are smoking or not on an ongoing basis.  
 
One GP is passionate about smoking cessation and asks every patient at every visit. He states that when his 
patients “see him in the street they throw away their cigarettes”! Some of those GPs who use the first 
strategy felt they could pick up patients who smoke by stains on their fingers or the smell of cigarette smoke 
on the patient.  
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All the GPs advise their patients who smoke to stop. This usually takes a few minutes as part of the 
consultation and takes the form of education about the types of illness smoking can cause. Some try to 
frighten their patients by pointing out terrible consequences like “needing an amputation”. One GP said her 
advice to stop smoking is so strong that a patient commented “I will tell all my friends who smoke not to see 
you!” Although one GP tries to find out the patients’ readiness to quit smoking none of the others used 
counselling strategies like motivational interviewing. Some of the GPs only offered advice if the patient had 
a smoking related illness. Only one of the GPs recommends nicotine replacement therapy but all recommend 
bupropion therapy if the patient can afford it. All the GPs said they had good results with bupropion therapy. 
Only one of the GPs followed up patients specifically about their smoking, two weeks after giving smoking 
cessation advice. The others said they would enquire about their patients’ smoking habits when they 
presented again for another illness. 
    
Six of the GPs interviewed felt giving smoking cessation advice was worthwhile, while the other five were 
pessimistic about how effective this advice could be. Those who were negative about the effectiveness of 
smoking cessation advice felt that smoking was an addiction and that generally patients lacked motivation to 
stop smoking. Some felt that the patient would give up if they wanted to and advice from the doctor would 
not make a difference. They felt that it was too time consuming to spend time on smoking cessation advice or 
counselling. Three of the GPs were very pessimistic, expressing that advice from the doctor is not effective 
and it is only given because the doctor felt “morally obliged” to do so and that “whatever you do, you are 
doomed to failure”. Those who are positive about the value and effectiveness of smoking cessation advice 
felt that many patients are motivated to stop smoking and succeed with help and advice from the doctor. One 
of the older GPs felt that motivation to stop smoking these days was far higher than “it used to be in the old 
days”. He thought the reason for this was “there is much more media coverage these days” and motivation is 
getting better “due to increased public awareness” of the harms of smoking.  
 
Screening for breast cancer 
 
a) Literature review: Recommendations on screening for breast cancer 
 
The burden of breast cancer is significant and therefore it should be screened for. In North America it is the 
second leading cause of death from cancer. About 1 in 8 women are diagnosed with breast cancer at some 
stage in their life and 1 in 30 die from breast cancer
3
. The incidence of breast cancer increases with age. Most 
women do not have associated risk factors or genetic markers
3
. Breast cancer is also the second most 
common cancer in sub-Saharan Africa after cancer of the cervix. It appears to be less common compared to 
Western countries but occurs at a younger age with most patients presenting late with advanced disease. Lack 
of screening programs is one of the reasons for these late presentations
23
. 
 
Screening for breast cancer involves doing routine clinical breast examinations, teaching patients to do breast 
self-examinations and routine mammography. The USPSTF recommends women over the age of 40 should 
have a mammogram every 1 to 2 years. They recommend that women should be informed about the possible 
benefits and harms of mammography before deciding when to start screening. They state that there is 
insufficient evidence available at present to recommend for or against doing routine breast examinations or 
self-examinations by the patient to screen for breast cancer
3
. Research comparing clinical breast examination 
to screen for breast cancer compared to no screening is limited. Evidence is also lacking regarding the benefit 
of adding clinical breast examinations to mammography. Therefore it is impossible to determine whether the 
benefits outweigh the potential harms
3
. Breast self-examination does not reduce mortality from breast cancer 
and is potentially harmful because of the increased risk of false positive results and unnecessary biopsies
3
. A 
Canadian task force on preventative health care found that the harms of teaching breast self-examination out 
way the benefits and they recommend against teaching breast self-examination at routine annual health 
checks
24
. They suggest that only if a woman asks to be taught breast self-examination should she be shown 
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how to do it and that the benefits and harms must be clearly explained to her before hand. She should be 
shown how to do self-examination properly
24
. Mammography screening is more likely to benefit those 
women at greater risk of breast cancer like those with a family history of breast cancer; those with a first 
baby after 30 years of age or those with a previous abnormal biopsy of a breast lump
3
. The recommendation 
to start screening mammography at 40 years is strengthened by having had a relative with breast cancer 
before the onset of menopause.  There is insufficient evidence to recommend screening for the gene 
mutations associated with an increased risk of breast cancer or whether screening should be done earlier for 
these patients
3
.   
 
The National Health Service (NHS) Breast Screening Program in England screens women from 50 to 70 
years of age with mammography every 3 years because they feel there is sufficient evidence that this reduces 
mortality
25
. They screen about 1.3 million women each year and detect about 10 000 breast cancers per year. 
They have found that screened women are slightly more likely to be diagnosed with breast cancer than 
unscreened women and that the cancers are smaller and less likely to need mastectomy. They save one life 
from breast cancer death for every 400 women they screen over 10 years, thus saving 1400 lives a year in 
England
25
.  
 
A review in 1991 by Elixhauser into the cost effectiveness of screening for breast cancer found that mass 
screening by mammography improved early detection by 15 to 35%. The estimated cost of screening was 
between $13 200 and $28 000 per life year saved. The review found that screening was more cost-effective 
than not screening when all health care costs were taken into consideration but that the cost effectiveness of 
screening between the ages of 40 and 49 years was controversial
26
.  Screening for breast cancer using 
mammography is expensive. Stout et al found that screening cost $166 billion dollars between 1990 and 
2000, gaining 1.7 million quality adjusted life years at a cost of $62.5 billion compared to doing no 
screening
27
. In a recent analysis of cost effectiveness of breast cancer screening in India it was found that 
breast examinations done every year between the ages of 40 to 60 years were almost as effective at reducing 
mortality as doing mammography screening every 2 years at only half the cost
28
. Every year of life saved by 
the NHS Breast Screening Program in England costs about 3000 pounds
25
. 
 
Research results show a large variation in sensitivity and specificity of screening tests for breast cancer
3
. 
Sensitivity of mammography varies from 50 to 95%. Sensitivity is lower in younger women, those whose 
breasts are denser, and those on hormone replacement therapy. Specificity varies between 93 and 96% and is 
improved by screening more often and being able to compare previous mammograms. The sensitivity of 
clinical breast examinations varies from 40 to 70% and the specificity from 88 to 99% in different trials
3
. 
One large study found that only 4% of women with suspected cancer on breast examination turned out to 
have cancer. Sensitivity and specificity of self examinations are difficult to study and are therefore not 
known
3
. The potential harms of breast cancer screening are the anxiety, unnecessary biopsies, inconvenience, 
discomfort and cost associated with false-positive results
3
. The majority (80 to 90%) of abnormal 
mammograms or breast examinations turn out to be false positives. There is a possible risk of breast cancer 
being induced by the radiation of repeated mammography but this has not been adequately studied to 
determine what the risk is
3
.  
 
There is uncertainty about what age to start screening for breast cancer using mammography
3
. There is very 
good evidence that mammography every 1 to 2 years reduces mortality significantly. However most of these 
trials have been done on women older than 50 years. The evidence of a reduction in mortality in those aged 
40 to 50 is weaker and the benefit is smaller than those older than 50 years because the incidence of breast 
cancer is much lower in those under 50 years. The benefits of mammography increase with age while the 
harms decrease. It is unclear at exactly what age the benefits outweigh the potential harms. The specific 
screening interval for women between 40 and 50 years is also unclear. Screening with mammography after 
the age of 70 has not been well researched. Older women are at increased risk of developing and dying from 
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breast cancer but are also at increased risk of dying of other causes. Screening after the age of 70 years is 
therefore not recommended
3
.  
 
The research into the effectiveness of mammography does not provide clear unequivocal evidence that it 
reduces mortality. A Cochrane Collaboration review
3
 found that most of the trials were of a poor quality and 
that the pooled results of the only 2 good quality trials were not sufficient to prove that there is a benefit from 
mammography. The trials show a reduction in mortality ranging from 0 to 32%. Only one trial has looked 
specifically at the benefit of screening women between the ages of 40 and 49 years and they found mortality 
from breast cancer was not reduced using annual mammography and breast examinations
3
. 
 
Recommendations: Reviewing the literature shows that the burden of breast cancer is high indicating that 
screening is recommended. Annual breast examination and mammography every 3 years in women between 
the ages of 50 and 70 years is appropriate. Breast self-examination is not recommended unless patients 
request to be taught to do so and then harms and benefits must be explained to them.  
 
b) Interview results: Strategies used by GPs in Grahamstown to screen for breast cancer 
 
Three of the eleven GPs interviewed do not screen for breast carcinoma. They examine patients or refer for 
mammography if a patient complains of a lump. They refer well patients for mammography only when they 
ask to be referred. One of these GPs felt mammography “doesn’t pick up that much”. One of these GPs does 
screen those with a family history of breast carcinoma by doing routine breast examinations. All of the other 
eight GPs recommend breast self-examination frequently: “monthly” or “every time they are in the shower”; 
and screen all women routinely by examining their breasts annually. Those who do routine annual checks 
include breast examinations from the age when the patient first starts attending for these  at about the age of 
20 to 30 years when they start coming for their PAP smears. These GPs who screen for breast cancer use a 
wide range of strategies when it comes to mammography for patients who are not at high risk. One of them 
does not refer for routine mammography at all believing that an “experienced doctor is as accurate as a 
mammogram” in detecting early breast cancer. The others all refer patients for routine mammograms but 
vary from which age they recommend a patient should start. The youngest recommended age to start routine 
mammogram screening amongst the GPs is 30 years and the oldest 50 years. The frequency that the GPs 
recommend repeat mammograms for screening also varies. Three of the GPs recommend annual 
mammograms while the others recommend repeating every 2 or 3 years. All the GPs stated they screen their 
high risk patients more intensely than those not at high risk. 
 
None of the GPs interviewed keep a register or send reminders to patients to attend for breast cancer 
screening. Those that screen annually rely on the patient to return for their annual check up. None of the GPs 
involve their patients in decisions about screening by discussing the potential benefits, limitations and 
possible harms before hand. They all recommend the screening, stressing the potential benefit of excluding 
breast cancer or diagnosing it early. Most will discuss the possibility of a detected lump not being cancerous 
(false positive results) once the screening has detected it. All the GPs who screen for breast carcinoma said 
their patients accepted the breast examinations and mammograms. One did indicate that his patients who 
know him socially prefer to go to a colleague for breast examinations. One of the GPs who does not screen 
feels that women do not find it acceptable for him to do routine breast examinations. All the GPs noted that 
their more disadvantaged patients are screened at a much lower rate than their more advantaged patients, if at 
all. Various reasons were given for this including that the patients are less informed and do not demand 
screening, attend the GP for mainly curative problems and not being able to afford mammograms.  
 
 
 
 
Stellenbosch University  https://scholar.sun.ac.za
 16 
Screening for cervical cancer 
 
a) Literature review: Recommendations on screening for cervical cancer 
 
Secondary prevention of carcinoma of the cervix involves doing cytology smears (Papanicolaou or PAP 
smears) as part of screening in general practice. Although PAP smears are used mainly to diagnose cancer of 
the cervix and detect precancerous lesions they also can provide information about gynaecological infections 
and can be used to monitor treatment
29
. 
 
Screening for cervical carcinoma can be justified because it is a common and serious public health problem. 
Cervical cancer is the most common cancer causing death in sub-Saharan Africa
30
. In 2002 about 500 000 
new cases of cancer of the cervix were diagnosed with approximately 274 000 deaths world wide. 
Approximately 83% of these were in developing countries where carcinoma of the cervix makes up about 
15% of all cancers, compared to 3.6% in developed countries
30
. The Cancer Registry of South Africa 
documented 5203 new cases of cancer of the cervix in 1999. This was 17% of all cancers in women. 84% of 
patients were black with an estimated 1 in 21 black women being at risk of cervical cancer
30
. The marked 
difference of cervical cancer rates in developed countries is attributed to mass cervical cancer screening 
programs.  
 
Estimates of sensitivity and specificity of PAP smears to detect squamous carcinoma of the cervix vary 
greatly
31
. Estimates for sensitivity range from 11% to 99% and specificity 14 to 97%. It is not possible to get 
high specificity and sensitivity at the same time using PAP smears to diagnosis carcinoma of the cervix. 
Specificity in the range of 90-95% corresponds to sensitivity of 25-30% 
31
. Thus PAP smears are more useful 
to rule in disease than rule out disease.  
  
Recommendations for when to screen vary greatly probably because evidence is limited. The United States 
Preventative Services Task Force (USPSTF) suggests most of the benefit can be obtained by beginning 
screening within 3 years of onset of sexual activity or age 21 (whichever comes first) and screening at least 
every 3 years
3
. They found limited evidence that screening in women older than 65 who had had normal pap 
smears was worthwhile. They recommend annual testing in symptomatic women and those at high risk like 
those with HIV and/or HPV infections and those who have many sexual partners
3
. Recommendations or 
guidelines for cervical cancer screening in South Africa are lacking but it has been shown that more than 
80% of cervical cancers and related deaths can be prevented by organized regular population based PAP 
smear screening that is provided at intervals of 3 to 5 years
29
. The high prevalence of human 
immunodeficiency virus (HIV) and human papilloma virus (HPV) infections in South Africa and the 
association of cervical carcinoma with these infections increase the burden of this disease, making screening 
even more important.  
 
 
 
The screening procedure is uncomfortable and therefore patients may have reservations about having them. A 
large number of women avoid or delay having pap smears. The treatment of dysplasia is acceptable, 
affordable, safe and effective for most patients. Further investigations and the treatment of detected 
premalignant lesions form an essential part of screening. Approximately 99% of cervical cancers can be 
prevented by treatment of premalignant lesions
29
. Cervical carcinoma has a prolonged pre-symptomatic 
phase with progression from pre-invasive condition to invasion taking as long as 10-20 years
29
. Treatment 
can dramatically change the course of the disease and only treating the disease in the symptomatic phase 
results in high morbidity and mortality. The United States Preventative Services Task Force (USPSTF) 
strongly recommends screening for cervical cancer in women who have been sexually active and have a 
cervix. They found good evidence that screening with cervical cytology reduces incidence of and mortality 
from cervical cancer and conclude that the benefits of screening substantially outweigh potential harms
3
. 
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Research indicates that GP and patient reminders are recommended to encourage women to have regular 
PAP smears
31
.Thus a register of patients who require pap smears is advisable
32
.  
 
There appears to be controversy over including HPV testing in screening for cervical cancer. The American 
Cancer Society and American College of Obstetricians and Gynaecologists recommend combined HPV and 
Pap smear testing to screen for cervical cancer
33
. However there is no evidence to support the use of HPV 
DNA testing as a primary screening tool for cervical cancer or for testing women with equivocal Pap smear 
results
34
. A Cochrane review of 40 studies found that using a combination of a cytobrush and an extended tip 
spatula is the most effective technique for collecting PAP smears. This combination achieved better rates of 
detecting endocervical cells than the commonly used Ayre spatula
35
. Although liquid based cytology has 
become popular for cervical carcinoma screening it is still unclear whether this is better than smear 
technology. A review and meta-analysis of studies between 1991 and 2007 found that liquid based cytology 
was neither more sensitive nor specific than Pap smear in detecting high grade cervical intra-epithelial 
neoplasia
36
. The USPSTF states that at present there is insufficient evidence to recommend for or against new 
technologies or routine testing for HPV to screen for cancer of the cervix
3
. 
 
In a review of cervical cancer screening in the developing world Cronje notes that cervical cancer is still the 
most common cancer in low income countries because of the inadequacies of screening. Important factors 
contributing to this are the relatively high costs; low sensitivity; need for expertise and the logistics of mass 
PAP smear screening. However he does go on to point out that there is not a more advantageous screening 
method
37
. In a review of cervical cancer screening methods in less developed countries Mandelblatt et al 
compared the costs and benefits of the different strategies used. They found that all strategies saved lives, 
reducing mortality by up to 58%. Visual inspection of the cervix after applying acetic acid (VIA) was the 
least expensive at 517 US dollars per life year saved compared to a combination of PAP smear and HPV 
testing which cost 1683 US dollars per life year saved. VIA achieved 83% reduction in mortality whereas 
combination of PAP and HPV testing could achieve greater than 90%. They found PAP smear was a cost 
effective alternative costing less than 1000 US dollars per life year saved if sensitivity is above 80%. They 
recommended that less developed countries can reduce mortality at low cost by having a well organised 
screening program. Optimal policies need to be made appropriate for the given setting
38
.  
 
Recommendations: Cervical cancer is common and the morbidity and mortality is greatly reduced by 
screening. PAP smears should be started from within 3 years of the onset of sexual activity or age 21 and 
repeated every 3 to 5 years in women who are not at increased risk. Those at increased risk should have PAP 
smears annually. It is not necessary to continue doing PAP smears after the age of 65 years if the patient has 
had normal smears throughout life. Patient registers and reminders are recommended to improve screening 
rates. 
 
b) Interview results: Strategies used by GPs in Grahamstown to screen for cervical cancer 
 
All the GPs interviewed screen for cervical carcinoma with PAP smears. They start screening when the 
patients become sexually active or at the age of about 18 to 20 years. One of the GPs pointed out that it is 
sometimes difficult to get the screening started because one is not always sure if the young women are 
sexually active or how they will respond to the recommendation. She stated that, “it is not so easy when you 
see young people to start with PAP smears”. Three of the GPs said they screen in a targeted way by 
recommending PAP smears only when women present with gynaecological symptoms. All the others 
recommend routine regular PAP smears. Six of the GPs recommend repeating normal PAP smears annually 
on all women whether at increased risk of cervical cancer or not. One GP recommends them every 2 years 
and the other every 3 years. All the GPs screen throughout life except for one who stops screening at age 60 
years if the woman’s PAP smears have been normal. One commented that “while they have a cervix they 
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need a PAP smear”. One of the GPs does a vaginal examination annually at the time of Pap smear feeling 
that “checking for ovarian cancer is more important in the type of patient we see”. 
 
None of the GPs spend time discussing the potential benefits and harms of screening before doing PAP 
smears. All the GPs do the PAP smears themselves and all but one, who uses the Ayres spatula, uses the 
cytobrush. None of the GPs use liquid based technology or blood tests for HPV to screen for cervical 
carcinoma. None of the GPs keep a register of patients needing PAP smears or send patient reminders. They 
all rely on the patient to remember to return for repeat PAP smears. One of the GPs who recommend annual 
PAP smears commented that when he checks on when his patients had their last smear often a few years have 
gone by.  
 
One of the GPs who do not do PAP smears routinely on healthy women does them annually on HIV positive 
women. The GPs who screen regularly do not identify those at high risk but instead screen everybody 
intensively. Some of them commented on how difficult it is to know if patients had multiple partners and 
were therefore at increased risk of cervical cancer. One commented, “Nobody is going to tell you they have 
multiple partners”. One GP presumes all the young women have multiple partners and screens them annually 
and once they marry or settle down with one partner starts to extend the interval he recommends between 
PAP smears. All the GPs commented that although their patients were sometimes reluctant to do PAP smears 
and delayed doing them, they generally find the procedure acceptable and get them done.   
 
Screening for colorectal cancer 
 
a) Literature review: Recommendations on screening for colorectal cancer 
 
There are several options to screen for colorectal cancer. These are faecal occult blood testing, flexible 
sigmoidoscopy, colonoscopy, barium enema, computed tomography, virtual colonoscopy and stool DNA 
extraction. This is secondary prevention to detect colon cancer early and thereby reduce mortality from this 
condition. Faecal occult blood testing can take place as a side-room investigation or as a specimen sent to the 
laboratory for testing. A detailed family history forms part of screening to identify those at increased risk of 
colorectal cancer. Those with familial adenomatous polyposis and hereditary non-polyposis colon cancer 
need to be referred early to specialists for more intensive screening and follow up.   
 
Colorectal cancer poses a significant public health problem. Worldwide approximately 850 000 people are 
diagnosed with colorectal cancer each year and 500 000 die from it anually
39
. It is the second leading cause 
of death from cancer in the United States. A 50 year old has a 5% chance of getting colorectal cancer and 
death from it costs on average 13 years of life
39
. About 20% of colorectal cancers are familial with 70% 
occurring on a sporadic or non-hereditary basis
39
. The rate of colorectal cancer has been lower in black than 
white patients in South Africa but, possibly due to changes in diet, the occurrence in the urban African 
population is rising
40
. Rates of colorectal cancer are higher among blacks in westernised countries. For 
instance the rates in African Americans are slightly higher than for whites
41
. This makes screening in South 
Africa more important than it has been in the past. 
 
There is a pre-symptomatic phase of the disease when the pre-cancerous lesion is a polyp which is difficult to 
differentiate from cancer. Once this has become malignant there is a short lead time before the prognosis 
begins to deteriorate. Therefore it has to be picked up early to improve outcome making it necessary to test 
frequently. Thus faecal occult blood testing has to be done annually to be worthwhile. The USPSTF 
recommends screening men and women over 50 years for colorectal cancer as they found evidence this 
reduces mortality
3
. All methods of screening mentioned above have evidence they reduce mortality except 
for computed tomography
3
. In a review of colorectal cancer screening methods including occult blood tests, 
sigmoidoscopy, colonoscopy, double-contrast barium enema, virtual colonoscopy and faecal DNA, Walsh et 
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al found there was good evidence that screening for colorectal carcinoma was worthwhile and reduced 
mortality but there was not evidence that one test was better than any of the others
42
. Faecal occult blood 
testing is obviously the cheapest and least invasive of these. They recommend screening should include an 
annual faecal occult blood test, flexible sigmoidoscopy every 5 years and colonoscopy every 10 years for the 
average risk population. The best evidence for colorectal cancer screening is for the use of faecal occult 
blood testing and flexible sigmoidoscopy
43
. Routine colonoscopy has not been shown to improve mortality 
but has the most accuracy as a single test. Therefore colonoscopy should be used as the last test in the 
investigation and treatment of patients with other abnormal tests. Double contrast barium enema, CT 
colonography and faecal DNA testing need further evidence before they can be recommended for routine 
screening
43
. There is evidence that screening should continue until age 75 years
43
. 
 
There are patients with increased risk factors like those with a family history of colorectal cancer, familial 
polyposis and ulcerative colitis who require more intensive screening. It has been recommended that those 
patients who have had a first degree relative with colon cancer start annual screening earlier at age 40 and 
those whose family member had cancer before age 50 start screening at an age 10 years earlier than the age 
the family member developed the cancer
39
.  
 
Generally screening rates for colorectal cancers are poor, particularly in lower-socioeconomic communities. 
Wolf et al found that only 7% of people in low socio-economic areas of Chicago were appropriately screened 
by physicians at Federal Health Centres. Among those who did receive a recommendation from their 
physician 76.2% had completed a screening test (primarily faecal occult blood test-94.1%). They concluded 
that organizational interventions needed to be made to promote screening recommendations in medically 
underserved areas
44
. Even in medically well served areas screening rates are poor because of physician 
failure to recommend screening and poor patient adherence. Ling et al showed enhanced practice and patient 
management with a register and recall system improving colorectal cancer screening adherence 
significantly
45
. Most patients find faecal occult blood testing acceptable and are willing to undergo the test 
but find the invasive procedures less acceptable because of discomfort, the preparation required and risk of 
complications
3
. A multi-centre study in Australia found that participation in screening was significantly 
higher in those using faecal occult blood testing than the other more invasive methods
46
. Some patients might 
not like the idea of producing stool specimens but if an explanation is given to them regarding the rationale 
behind the testing most find it acceptable. It is feasible and widely available in most areas
47
. Many patients 
may not be prepared to undergo the more invasive tests for screening purposes.  
 
Annual faecal occult blood testing reduces mortality by more than 20%. It also results in the reduction of the 
incidence of colorectal cancer by up to 20% by detecting large adenomas which can be removed
48
. The 
prognosis of colorectal cancer mainly depends on the stage at diagnosis. Cancers detected at an earlier stage 
having a better prognosis
49
. It is logical that patients would prefer earlier detection and therefore earlier 
treatment as this improves the morbidity and mortality associated with the disease and its treatment.  
 
Side room faecal occult blood testing is less sensitive and specific than laboratory testing. The reason for this 
is it is only one test and is done on a specimen from rectal examination which may be inadequate or contain 
blood from trauma caused by the examination. Some studies show laboratory faecal occult blood testing has 
a sensitivity of 40 – 60 % and specificity of 90 – 98 %45. The advantage of faecal occult blood testing is the 
ability to detect most early colorectal cancers and significantly reduce mortality
45
. Some studies report a 
lower specificity meaning many false positive screens
47
.The disadvantages being that it misses half the 
cancers and many unnecessary colonoscopies are done on those without cancer. DNA markers in the stool 
are highly sensitive and much more specific than faecal occult blood tests but have not been adequately 
researched to be recommended for routine screening and are still extremely expensive
48
. Although the other 
tests are more sensitive and specific than faecal occult blood tests, they are invasive and therefore if used for 
screening also result in a large number of unnecessary procedures. For instance screening with 
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sigmoidoscopy detects 8 cancers for every 1000 examinations and colonoscopy results in many patients 
having polyps detected or removed but only a small percentage would have developed cancer
50
. The invasive 
procedures have the potential harms of sedation/anaesthesia and complications from the procedures, although 
these are rare. Thus faecal occult blood testing is the best method available to screen asymptomatic people at 
average risk who would then need colonoscopy if positve
46
. Virtual colonoscopy has a high sensitivity in 
detecting colorectal cancers although this varies from centre to centre as experience of using the technology 
grows. It can therefore be used to investigate patients who are faecal occult blood positive to screen out those 
who do not have cancer. If no cancer is detected it enables the patient to avoid colonoscopy which could be 
reserved for those needing therapeutic intervention
48
. 
 
Faecal occult blood testing is cheap and extremely cost-effective
46
. A pilot study of over 250 000 people in 
the United Kingdom detected colorectal cancer in 0.16% with faecal occult blood testing and therefore 
concluded routine testing would lead to a decrease in mortality from the disease
49
. A more recent study 
looking at the value of offering screening found that if 4 million people were offered screening as 
recommended about 31 500 deaths would be prevented and 338 000 years of life would be gained. They 
conclude that colorectal cancer screening is “a high-impact and cost-effective service”50. Frazier et al 
compared several strategies recommended by an expert panel for screening for colorectal cancer in average 
risk people. They found the most cost effective strategy is annual faecal occult blood testing plus 
sigmoidoscopy every 5 years (followed by colonoscopy if a low or high risk polyp is found) from 50 to 85 
years
46
. This results in a 60% reduction in cancer incidence and 80% reduction in cancer mortality compared 
with no screening
51
. All other recommended strategies were either less effective or significantly less cost 
effective
52
. 
 
Recommendations: The burden of colorectal cancer is significant and increasing in the black population. 
Screening has been shown to significantly reduce mortality. Research shows that a cost-effective screening 
strategy is faecal occult blood testing annually, sigmoidoscopy every 5 years and colonoscopy every 10 years 
between the ages of 50 and 75 years for those at average risk. High risk patients should be screened more 
intensively.    
 
b) Interview results: Strategies used by GPs in Grahamstown to screen for colorectal cancer 
 
Only one of the GPs interviewed screens for colorectal cancer. The reasons given by the GPs for not 
screening were varied. Some felt that patients would find the screening process unacceptable because they 
would find producing stool specimens embarrassing and colonoscopy uncomfortable. The other main reason 
given for not screening was that the GPs felt “unsure about the evidence for colorectal screening” or being 
“unsure about the pick up rate” of stool occult blood testing. The one GP who screens does stool occult 
blood testing on all patients older than 55 years of age. He refers patients for sigmoidoscopy or colonoscopy 
if the stool occult blood is positive. He does not refer for sigmoidoscopy or colonoscopy routinely at any 
stage. He commented “what is frustrating is how many positives (stool occult blood tests) I get and send 
them to a colorectal specialist and they don’t find anything”. 
 
All the GPs investigate patients for colorectal cancer when they have symptoms that could be caused by the 
disease, like altered bowel habit or abdominal pain. They all consider high risk patients to be those whose 
relatives had colorectal cancer and refer them to specialists for screening and follow up. 
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Screening for hyperlipidaemia 
 
a) Literature review: Recommendations on screening for hyperlipidaemia 
 
Screening for and treating hyperlipidemia is secondary prevention to prevent cardiovascular disease, 
particularly coronary artery disease. Screening involves history, examination and blood testing. Important 
risk factors on history are diabetes, family history of cardiovascular disease at a young age and/or 
hyperlipidemia and other risk factors for coronary heart disease like smoking and hypertension
53
. 
Examination for xanthelasma, arcus cornealis and xanthomata are important to detect possible 
hyperlipidemia
54
. Initial screening involves testing non-fasting cholesterol and high density lipoprotein-
cholesterol (HDL). If these are elevated a fasting lipogram including triglyceride level is done
55
. Overall risk 
factors for heart disease like age, sex, diabetes, hypertension, family history and smoking must be considered 
when deciding on treatment, rather than only considering the lipid levels. Treatment involves diet initially 
and drug therapy for those who do not achieve therapeutic goals, especially those at high risk. All modifiable 
risk factors should be addressed simultaneously
53
. 
 
The USPSTF recommends screening all men 35 years and older and women 45 years and older for 
hyperlipidaemia and offering treatment to those who are at increased risk of coronary heart disease, because 
there is good evidence that measuring lipid levels can identify asymptomatic people at increased risk of 
coronary heart disease and that lipid-lowering drug therapy decreases the incidence of coronary heart disease 
in such people. They feel the benefits definitely outweigh the harms
3
. They also feel younger adults (men 20 
to 35 and women 20 to 45) should be screened if they have other risk factors for coronary heart disease. The 
optimal time interval between screenings is uncertain but it is reasonable to test every 5 years. Those at high 
risk or needing treatment should be tested more frequently. Repeated screening in people over 65 who have 
previously had normal tests is not recommended because lipid levels are less likely to increase after 65 
years
3
. 
 
Coronary artery disease is the leading cause of morbidity and mortality worldwide
53
. Dyslipidaemia and 
coronary heart disease have reached epidemic proportions in whites, coloureds and Indians and is rapidly 
increasing in blacks in South Africa
56
. Evidence suggests that dyslipidaemia is not just a risk factor for 
coronary heart disease but a cause. It has been noticed in South Africa that patients with familial 
hypercholesterolemia, dyslipidaemia alone, without other risk factors, can cause severe and premature 
coronary heart disease and that in blacks without dyslipidaemia coronary heart disease is rare despite the high 
prevalence of hypertension, smoking and diabetes
56
. Thus hyperlipidaemia is a serious health problem 
warranting preventative measures. There is a pre-symptomatic phase of the disease when hyperlipidaemia 
can be detected and treated before coronary artery disease occurs. There is evidence that lipid lowering 
interventions with lifestyle changes or drug therapy reduce the rates of cardiovascular events
53
.  
 
There is adequate participation of the target population in screening but many do not find the treatment 
acceptable. Many find it difficult to change their lifestyle and diet. The minority of patients achieve 
significant lipid lowering with diet alone and most need drug therapy
3
. The statins are the first choice drug 
therapy and are very effective. Six major trials involving over 30 000 patients have shown a decrease in 
coronary artery disease morbidity and mortality, stroke and peripheral vascular disease
53
. Cost is a limiting 
factor for those who are not on a medical aid which will pay for them, but recently prices have come down 
significantly in South Africa. They are cost effective in terms of the cost of disease morbidity they prevent. 
The statins are safe drugs with the ratio of lives saved to those lost being 100 000 to 1, therefore justifying 
lifelong clinical use in those who need it
53
. Hepatotoxicity (0.5%) and myopathy (<0.5%) are the 2 main 
side-effects which may limit their use. Normal values for hyperlipidaemia are well established making 
sensitivity and specificity high but care has to taken when and how blood specimens are taken and handled
55
. 
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Recommendations: South Africa has a high rate of dyslipidaemia and coronary artery disease making 
screening worthwhile. Prevention strategies should include history and examination. Research shows that 
testing for hyperlipidaemia should be started at age 35 years for men and 45 years for women and repeated 
every 5 years until the age of 65 years if normal . Patients at high risk or with abnormal results should start 
screening earlier and test more frequently. 
 
 
b) Interview results: Strategies used by GPs in Grahamstown to screen for hyperlipidaemia 
 
All the GPs interviewed screen for hyperlipidaemia. One GP commented that screening for cholesterol is a 
“current favourite, everybody asks for it” and that he is “screening masses”. Five of the GPs only screen 
patients with other risk factors for ischemic heart disease or those who request cholesterol testing. The others 
routinely recommend screening to all their patients. Most GPs screen with a fasting lipogram, while 3 of the 
GPs prefer to do random total cholesterol as the initial screening test and only do the fasting lipogram if this 
is elevated. One GP stated he preferred this approach because, “I’m more likely to capture the patient if I do 
non-fasting”. None of the GPs use finger prick testing for cholesterol, one stating that finger prick 
cholesterol is “notoriously inaccurate”. 
 
The GPs start screening for hyperlipidaemia at ages varying from 30 to 50 years. None of the GPs have a cut 
off age when they no longer screen. All start screening those at higher risk younger than those without risk. 
All the GPs screen the high risk patients annually and six of them screen both high and low risk patients 
annually. Those who screen even the low risk patients annually do so as part of the annual health check. They 
seem to do this because it is convenient and easier to remember annually as part of a routine health check. 
One GP felt that as the test is inexpensive an annual check is useful as a reminder to the patient about their 
health and if the result is normal it encourages them to stay healthy. He stated that “the fact that he is doing 
something positive towards his health, that kind of good news does so much good …it’s a reminder … rather 
than waiting for things to happen to you, you are making things happen”. One GP recommends repeat 
screening every 3 years for those without risk factors while the others leave the timing of repeat testing up to 
the patient.  
 
None of the GPs keep a register or have a recall system for hyperlipidaemia screening. All of the GPs 
recommend lifestyle change in the form of diet and exercise before resorting to drug therapy. Some said 
many of their patients were reluctant to take medication for hyperlipidaemia but all the GPs said that those 
that were put on medication generally tolerated it well. All the GPs discuss the advantages of and reasons for 
screening for hyperlipidaemia but not the disadvantages. All the GPs interviewed were pessimistic about 
their patients’ ability to change to healthy lifestyles. They noted that very few succeeded in making a 
sustainable change. One commented that diet and exercise seems to be “one of the most difficult changes to 
make”. Another felt that “eating habits are like an addiction which patients find difficult to change”. All the 
GPs acknowledged that their more disadvantaged patients are screened at a much lower rate and some said 
not at all. One commented that they do not demand screening because “they may not have access to 
information”.  
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Screening for prostate cancer 
  
a) Literature review: Recommendations on screening for prostate cancer 
 
Prostate cancer is common. About 1 in 6 men in the United States are diagnosed with it in their life time. In 
2007 about 200 000 men in the United States were diagnosed with cancer of the prostate and approximately 
270 000 died of the disease in 2006
3
. The average age of death from prostate cancer was 80 years with most 
men (71%) dying after the age of 75 years. Many cases of prostate cancer detected by screening would never 
cause symptoms during the patient’s lifetime. Studies show that prostate-specific antigen (PSA) screening 
over diagnoses prostate cancer by up to 40% causing a significant burden on this group of the population
3
. In 
sub-Saharan Africa prostate cancer is estimated to constitute about 10% of all cancers in men. The highest 
incidence occurs in Southern Africa at 40 per 100 000 males. In South Africa the incidence is 40 per 100 000 
white males and 14 per 100 000 black males
57
. However screening and diagnostic tests are less available to 
the black population. In America black males have the highest incidence of prostate cancer in the world, 72% 
higher than white Americans
57
. Histologically proven cancer of the prostate increased four fold between 1986 
and 1995 in South Africa probably because of improved screening methods like the use of the prostate-
specific antigen (PSA) test
57
. 
 
The prostate specific antigen (PSA) test is more sensitive in detecting prostate cancer than digital rectal 
examination
3
. However the PSA test cannot achieve both high sensitivity and specificity. Although the cut 
off point of 4ng/ml is widely used to indicate possible prostate cancer it is an arbitrary level without high 
sensitivity or specificity. No PSA level offers both high specificity and sensitivity. Lower cut off levels will 
detect more cancers but obviously result in many more false positive tests
3
. PSA tests improve early 
detection and help predict the risk of complications and monitoring treatment but there is no evidence they 
lower mortality of prostate cancer
3
. Using additional markers known as kallikrein markers may improve 
specificity and reduce cost by reducing the number of unnecessary biopsies
58
. An approach that has been 
suggested is to do a PSA in early middle age which can predict risk of prostate cancer later in life and 
indicate the intensity of screening that is appropriate for each individual
58
. Other methods of screening like 
PSA levels adjusted for age, free PSA and monitoring PSA increase (PSA velocity, slope or doubling) have 
not been shown to improve the outcome of prostate cancer
3
. The detection rate of prostate cancer by biopsy 
varies depending on how many biopsies are taken. Therefore it is difficult to assess the accuracy of screening 
tests. The specificity of a high PSA level appears to increase when more biopsies are done, but these result in 
more clinically unimportant cancers being detected. Thus the accuracy of the PSA in detecting clinically 
important cancer of the prostate is difficult to determine
3
. A retrospective study found that a PSA level above 
4 ng/ml had a sensitivity of 91% for detecting aggressive prostate cancer but only 56% for detecting non-
aggressive cancer. The same study showed a PSA cut-off of 4 ng/ml had a specificity of 91% for prostate 
cancer
3
. In a multicentred clinical trial of over 6000 men PSA was shown to detect more cancers, 82% than 
digital rectal examination (DRE), 55%. The cancer detection rate was 4.2% for PSA, 3.2% for digital rectal 
examination and 5.8% for the 2 screening tests combined. They concluded that optimal screening for prostate 
cancer is achieved by combining digital rectal examination with PSA tests and that a biopsy should be 
considered if the PSA is above 4ng/ml or the DRE is suspicious
59
. Carvalhal et al screened over 22 000 men 
and showed that digital rectal examination detects a significant number of potentially curable prostate 
cancers in patients with a PSA of 4 ng/ml or less
60
. 
 
PSA screening has been used for 20 years, increasing the detection of prostate cancer while it is still curable 
and thereby decreasing mortality. This has resulted in screening programs recommending PSA testing from 
as early as 40 years of age. The PSA is the best studied marker for detecting cancer of the prostate. However 
there is no good evidence from randomised controlled trials which show that this reduction in mortality 
outweighs the harms like the cost and morbidity associated with over diagnosis and treatment
61
. The 
USPSTF does not find sufficient evidence to show that the benefits of screening for prostate screening 
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outweigh the harms in men less than 75 years of age. While there is good evidence that the PSA can detect 
some cases of prostate cancer there is not clear evidence that patients detected by screening have a better 
outcome than those detected clinically when experiencing symptoms
3
. They also found that in men older than 
75 years the outcome of prostate cancer detected by screening compared to unscreened patients was 
negligible. Screening and treating prostate cancer detected by screening can result in harms which in many 
patients may not have occurred because the cancer may not have caused symptoms in their lifetime. These 
harms are anxiety associated with false positive results, pain and discomfort of unnecessary biopsies, erectile 
dysfunction, urinary incontinence and even death associated with treatment
3
. Thus in their recommendations 
the USPSTF conclude that there is insufficient evidence currently to recommend for or against screening for 
prostate cancer in men younger than 75 years and that they recommend against screening in men older than 
75 years. This is in keeping with a Cochrane review of the evidence for screening prostate cancer. They 
found there was not enough high quality research to determine whether screening improved mortality 
compared to no screening. They also found no randomised controlled trials on the harms and cost 
effectiveness of screening or the effects on patients’ quality of life62. 
 
The number of cancer cases detected decreases dramatically with repeated screening tests. If screening were 
shown to improve mortality screening every 4 years would be as beneficial as screening every year
3
. It is 
uncertain what the best treatment of possible prostate cancer detected by screening is
3
. Possible treatment 
options include observation with symptomatic treatment; actively monitoring biochemical markers and 
treating when the disease progresses; prostatectomy or radiation. It has been shown in men over 65 years at 
the time of prostate cancer diagnosis the mortality from the cancer at 10 years is the same between the group 
who were watched and those who had prostatectomy, which suggested there was no benefit from surgery in 
this age group
3
.  
 
Patients should be informed of the uncertainties regarding the benefits and the known harms of screening for 
cancer of the prostate so they can make an informed choice about whether to do PSA tests. If screening were 
shown to improve the outcome of prostate cancer, men between 50 and 75 years old would be likely to 
benefit the most
3
. It would take 10 years for men to experience a benefit in mortality, thus very few men over 
75 years would experience this mortality benefit. Also men younger than 75 years with chronic medical 
illness and a life expectancy less than 10 years are unlikely to benefit from screening and treatment
3
. In the 
United States most medical organisations recommend that screening strategies for prostate cancer should be 
chosen specifically for each individual after discussing the benefits and harms with them and finding out 
their preferences. They feel that it is appropriate to screen men over the age of 50 who have a life expectancy 
over 10 years and recommend offering PSA and digital rectal examination annually
3 
 
Recommendations: Cancer of the prostate is common in South Africa and therefore screening is appropriate. 
However it is important for GPs to be aware of the uncertainty regarding whether the benefits of screening 
outweigh the harms and explain this to their patients. If patients choose to screen for prostate cancer a PSA 
test and digital rectal examination every 4 years between the age of 50 and 75 years is appropriate. Screening 
men with chronic medical illnesses and a life expectancy of less than 10 years is not recommended.   
 
b) Interview results: Strategies used by GPs in Grahamstown to screen for prostate cancer  
 
All the GPs apart from two routinely screen for prostate cancer. The two who do not routinely screen 
investigate for prostate cancer when there are lower urinary tract symptoms. One of these GPs feels there is 
“not much benefit” to screening for prostate cancer. The nine GPs who screen for prostate cancer 
recommend the PSA test and three of these also do a routine digital rectal examination (DRE). The three 
female GPs say the male patients do not like them doing rectal examinations. One of the male GPs noted that 
“many people refuse to have it done anymore”. Those who do not recommend DRE feel it is no longer 
necessary because the PSA is more accurate and one stated that she “is not particularly good at doing DRE”. 
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All those who screen do so annually apart from one GP who recommends repeat tests every 2 to 3 years. The 
ages the GPs recommend starting screening range from 40 to 55 years and they all screen throughout life. 
Some of the GPs said they screen throughout life because the patients have a right to know whether they have 
cancer or not and that it is difficult to explain to a patient that one is no longer screening because they are at 
an age when they are more likely to die of some other condition. One GP also said he continued testing into 
old age to avoid litigation if a cancer was missed. 
 
None of the GPs keep a check list or register of patients needing tests and leave it up to their patients to 
return for repeat tests. Only one of the GPs interviewed involves his patients in decisions about screening by 
discussing the benefits and harms before testing. He says that despite pointing out the possible harms of false 
positive tests like anxiety and unnecessary biopsies his patients still want the tests done. All the other GPs 
discuss the benefits of diagnosing cancer of the prostate early but do not discuss potential harms of screening. 
Some say that patients are accepting of false positive results resulting in a negative biopsy and are grateful 
and relieved to be cleared of having cancer. One of the GPs who dose DRE noted that patients “don’t like it 
but get it done”.  All the GPs agreed that their more disadvantaged patients get screened at a lower rate.  
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Screening for human immunodeficiency virus (HIV) infection 
 
a) Literature review: Recommendations on screening for human immunodeficiency virus (HIV) 
infection  
 
Statistics published by the WHO in July 2008 estimated that worldwide 33 million people were living with 
HIV by the end of 2007. The South African Department of Health Study of 33 488 pregnant women 
attending antenatal clinics across the country found that about 28% of pregnant women were HIV positive in 
2007
63
. The South African National HIV Survey in 2005 estimated that about 10.8% of South Africans were 
living with HIV. (Africans 13.3%, Whites 0.6%, Coloureds 1.9%, Indians 1.6%). The prevalence among 15 
to 49 year olds was estimated to be 16.2%. Using both studies and other data UNAIDS/WHO estimated the 
prevalence among 15 to 49 year olds to be 18.1% at the end of 2007
63
. At the end of 2007 it was estimated 
that 22 million adults and children were living with HIV in sub-Saharan Africa with about 1.5 million dying 
from AIDS. South Africa was estimated to have 5.7 million people living with HIV with about 350 000 
deaths from AIDS in 2007
63
. With almost 1 in 5 adults being infected in South Africa and given that almost 
half of all deaths in South Africa are caused by AIDS,  HIV screening has become extremely important. The 
AIDS epidemic has not only caused a great deal of suffering and many deaths but also impacted significantly 
on social and economic progress in South Africa. The life expectancy has now dropped to 54 years
63
. The 
prevalence of HIV is stabilizing or even dropping slightly. Among teenage girls, the prevalence dropped 
from 16.1% in 2004 to 12.9% in 2007. This may be due to younger women practicing safer sex. However the 
prevalence has increased among older women over the same period
63
. 
 
The USPSTF recommends screening all adolescents and adults at increased risk for HIV
3
. Patients should be 
considered at increased risk if they live in an area of high prevalence or have any of the following risk 
factors: men who have sex with men; those who have unprotected sex with multiple partners; intravenous 
drug users; sex workers; partners of HIV positive people and patients treated with other sexually transmitted 
infections
3
. Patients who request an HIV test may have high risk behaviour they are unwilling to disclose and 
therefore should also be screened. Screening strategies should be tailored to the prevalence of HIV in the 
population being served with routine screening recommended for populations with high prevalence (>1%)
3
. 
While it is possible to identify a large proportion of those patients at risk many are missed who do not report 
risk factors because they are reluctant to disclose high risk behaviours or do not know their partner has put 
them at risk. In 2006 the United States Centre for Disease Control recommended routine voluntary testing of 
all patients between the ages of 13 and 64 years attending health facilities. It was realised that only screening 
those with risk factors was inadequate as they estimated that as many as 25% of those infected with HIV 
were unaware of being infected
64
. 
 
Research has shown that screening populations with an HIV prevalence of 1% is cost effective in that the 
cost per quality adjusted life year is acceptable
65
. Screening for HIV (approximately $50 000 per quality 
adjusted life year (QALY) gained) is more cost effective than recommended screening for many other 
diseases like breast cancer ($57 500 per QALY gained); colon cancer ($57 700 per QALY gained) and type 2 
diabetes ($70 000 per QALY gained) 
65
. HIV screening is even more cost effective when one takes into 
account the added benefit of reducing transmission that may result from testing. Translating this to a high 
prevalence country like South Africa with a prevalence of over 10%, HIV testing is definitely cost effective. 
 
All standard HIV tests, including rapid tests, have a high sensitivity and specificity of over 99%
65
. False 
negative and false positive results do occur but are very rare. The accuracy of tests is the same for pregnant 
women and non-pregnant women and men. The enzyme-linked immunosorbent assay (ELISA) and Western 
blot test detect anti-bodies to HIV1 and 2 and are the most commonly used tests to diagnose HIV
66
. The 
WHO recommends using two separate ELISA or rapid tests to confirm HIV infection in areas where the 
prevalence of HIV is over 10%. They recommend three tests in areas of lower prevalence
67
. Because the 
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ELISA tests have become so accurate a Western blot test is no longer needed for confirmation of HIV 
infection. The Western blot assay for HIV-2 is the most accurate test to confirm HIV-2 infection
67
. The third 
generation HIV ELISA tests detect HIV from an early stage reducing the window period to 4 weeks
67
. Rapid 
HIV tests are now extremely accurate and because they are simple and do not require expensive laboratory 
equipment are very cost-effective. The WHO now allows for 2 or 3 different rapid HIV tests to be used to 
confirm a diagnosis of HIV infection. This gives results with similar high sensitivity and specificity as 
ELISA tests
68
. Thus rapid HIV tests are likely to be used more and more for screening. HIV ELISA and rapid 
tests on saliva and urine are currently used for surveillance but not diagnosis as they are not as accurate as 
blood tests. Polymerase chain reaction (PCR) tests detect HIV DNA with very high sensitivity and specificity 
from 2 weeks after infection. However they are technically difficult and costly to perform and are therefore 
not usually used for screening. PCR tests are useful for very early diagnosis; to verify indeterminate ELISA 
results and for screening of infants at an early age
67
. Many patients (up to 40%) do not return to get their HIV 
tests results. Where this is a problem rapid HIV tests improve the percentage of patients who get their result 
to over 99% because it is done while they wait. In fact it has been shown that patients prefer rapid tests
68
. The 
doctor needs to assess the clinical setting and individual patient’s preference when deciding on an HIV 
screening method.  
 
Most of the harm of screening for HIV is a true positive HIV result as it creates anxiety, tension with close 
relationships and stigmatisation. ARV treatment has many potential side-effects, the most significant being 
metabolic disturbance with increased risk of cardiovascular complications. These can be dealt with by 
changing regimes. The benefits of screening at risk patients definitely outweigh the harms
3
. There is good 
evidence that monitoring and treating patients detected to have HIV infection by screening with antiretroviral 
medication, when appropriate, improves their outcome. The progression of HIV disease and mortality is 
reduced in these patients
3
. 
 
It is uncertain what the appropriate duration between normal screening tests should be as research evidence 
and data on annual HIV incidence is lacking. The CDC recommends annual screening for those at high risk
64
. 
There is uncertainty about the value of screening adolescents and adults who are not at risk. Although there is 
evidence that more patients with HIV are detected, the yield is very low. Therefore the potential harms of 
screening could outweigh the benefits in those not at risk
68
.   
 
There is good evidence that routine HIV testing in pregnancy increases the number of women detected with 
HIV who can then receive treatment antenatally. There is also very good evidence that ARV medication 
taken before delivery is acceptable to patients and greatly reduces the rate of HIV transmission from mother 
to baby. Detecting HIV in pregnancy also gives the opportunity to plan an elective caesarean section and 
recommend avoidance of breast feeding which have been shown to reduce transmission of HIV to the baby. 
Current ARV regimes are safe for both mother and foetus except for efavirenz which can cause foetal 
abnormalities. Thus the benefits of screening all pregnant women far outweigh the harms
3
. 
 
Recommendations: Screening for HIV infection has become very important in South Africa because of the 
extremely high infection rates. All patients at risk should be screened with an HIV ELISA or rapid test. A 
positive result should be confirmed with a second test. The duration between screening tests should be 
chosen according to each individual patient’s ongoing risk of infection. All pregnant women should be 
screened for HIV. 
  
b) Interview results: Strategies used by GPs in Grahamstown to screen for human immunodeficiency 
virus (HIV) infection  
 
Most of the GPs interviewed do not routinely screen all adolescents and adults for HIV. They screen in a 
targeted way by recommending HIV tests to patients they consider at risk or who have symptoms or signs 
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suggestive of HIV disease. They do not make an assessment of risk by enquiring about the number of sexual 
partners a patient has or their sexual preferences. Instead they tend to decide who is potentially at risk based 
on their age and whether the GP knows they have a long term partner or not. The strategies they use are to 
have a low threshold for recommending tests on patients with any vague symptoms and those presenting with 
other sexually transmitted diseases. They also state that many patients request HIV tests. These GPs are 
concerned that recommending HIV tests routinely on all adolescents and adults may result in patients 
thinking that one is “insinuating they are promiscuous”. One GP commented for example that “to suggest to 
a farmer who has been married for 15 years he needs to do an HIV test is ridiculous”. So he recommends 
HIV tests when he “deems it appropriate” or the subject is “easily broached”. Thus some GPs are making 
the decision to screen based on what they know about their patients. Many of the GPs commented how their 
threshold for testing has got lower over the years and that they more readily recommend HIV tests now than 
they did a few years ago. Three of the GPs routinely recommend HIV tests on all adolescents and adults. 
They recommend HIV tests to their patients when they come for PAP smears and routine check ups. One of 
these GPs screens all sexually active patients because she feels that “anybody who is sexually active is at 
risk”. Another commented that the younger patients are “not at all fazed” when she recommends HIV tests. 
Some of the GPs stated that they do consider the prevalence of HIV infection of the population they are 
screening when recommending screening such that they “probably test more frequently” in high risk 
populations than low risk. Only one of the GPs recommended annual screening for HIV on his patients. All 
the others leave the frequency of repeat tests up to their patients. Regarding repeat tests after a negative HIV 
test, one GP commented that she “allows them to assess their own risk” and “many patients request an HIV 
test yearly and I don’t find that unreasonable”. 
 
Ten of the GPs screen with an HIV ELISA test. The other GP says she usually does a rapid test because 
many patients get anxious waiting longer for results. She said, “The anxiety of even waiting for one night 
often is too much”. She does a follow up ELISA if the rapid test result is doubtful or positive. All the GPs 
screen their pregnant patients for HIV. They all request an HIV as part of the antenatal blood screening tests. 
All apart from two specifically point out that an HIV test is being done and get consent to include it.  
 
All the GPs noted that many patients do not want to test for HIV and some are reluctant to use ART. 
However they also noted that HIV screening and treatment is being accepted more and more. One 
commented that “generally speaking a lot of patients are still unwilling to do the test” and that “I stress 
confidentiality” to try and make screening for HIV more acceptable to the patient. All the GPs stress the 
benefit of HIV testing but do not go into potential harms. Most of the GPs do not counsel their patients fully 
before testing and one acknowledged that, “I’m not so good at the counselling” for HIV testing.      
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General questions on screening 
 
Interview results: General questions on screening 
 
All the GPs apart from two find there is time to carry out recommended screening. One noted that one has to 
find the time to fit it in to avoid litigation. Those who do routine annual check ups say these provide ample 
time to do all recommended screening. The GPs who said they do not have time to carry out recommended 
screening say they are too busy doing curative work to fit it in their working day. Most of the GPs feel 
confident about which screening measures to recommend. However three of them commented that they 
would appreciate some general guidelines relevant to South Africa or an update on evidence regarding 
screening tests. All the GPs said they get asked by patients to carry out screening tests which they know are 
not worthwhile. They all tell their patients that the tests are not necessary but if their patients insist, do the 
tests anyway. One GP stated he tells his patients who ask for unnecessary tests “it’s a waste of time” but if 
they insist “I do them to reassure them”. Another GP said the problem is there are no protocols of what 
needs to be screened and when. She says this created problems where patients were recommended certain 
tests by one GP which are not recommended by another, even within the same practice and that this confuses 
the patients. Another said patients come requesting “all the tests you can do”. He says he does not debate 
because then “you are alienating the patient, you’re appearing to be a know all and patients don’t like that”. 
GPs say that patients get the idea these screening tests are necessary from friends, relatives, the internet and 
magazines.  
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DISCUSSION 
 
The results show that prevention strategies used by GPs in Grahamstown vary greatly and often do not follow 
what is recommended. This discussion compares the prevention strategies used by the GPs with the 
recommendations from the literature. 
 
Routine annual health check 
In keeping with research the interviews revealed that most of the GPs strongly recommend an annual routine 
health check to their patients as it gives him or her time to carry out recommended screening tests. However 
those GPs who do routine annual check ups tend to have a standard screening strategy rather than focussing 
on the individual’s particular health practices as is recommended9. Most are over screening their patients by 
doing a range of unnecessary tests every year. None of the GPs use check-lists to remind them which 
screening tests need to be done on each patient despite research showing these to be worthwhile
8
 
 
Some of the GPs do not do routine annual health checks because they practice mostly curative medicine and 
do not focus on prevention. They tend to perform screening tests in a haphazard way with the result that 
many of their patients are likely to miss out on recommended screening measures. There are those who do 
not do routine health checks but screen their patients adequately in a more directed way by targeting the 
specific risks of each individual (case finding or opportunistic care). However it is important for GPs to be 
aware that research shows that most patients want these assessments and, while there is not much evidence to 
show that sub-clinical illness is detected, it has been shown that they reduce patient worry about illness and 
improve the delivery of important screening tests
10
.  
 
Smoking cessation 
Similar to other research findings some of the GPs interviewed have negative beliefs and attitudes towards 
smoking cessation. They feel that such interventions are not worthwhile because patients generally lack 
motivation to stop smoking
17
. This is despite the fact that there is good evidence that screening and 
counselling to stop smoking is effective and the benefits outweigh the harms
19
. Although all the GPs I 
interviewed screen for smoking some only do so if the patient presents with a smoking related illness or signs 
that they smoke. It has been shown that GPs will fail to identify smokers if they use this strategy
18
. Although 
all the GPs offer advice to their patients to stop smoking, they spend only a few minutes of a consultation 
giving this advice despite evidence that the effect of counselling improves the longer one spends giving it
3
. 
None of the GPs used counselling strategies like motivational interviewing despite there being good evidence 
that these are effective
18
. Only one of the GPs recommends nicotine replacement therapy despite evidence 
that it doubles the numbers who stop smoking compared to counselling alone
21
. All the GPs recommend 
bupropion to assist patients to stop smoking and agree with research that it is effective
22
. Despite evidence 
showing that the more counselling sessions one has with a patient to specifically address their smoking habit 
the more likely they will abstain
3
, the GPs do not arrange follow up consultations to specifically address their 
patients’ smoking habits.  
 
 
Screening for breast cancer 
Some of the GPs do not screen women for breast cancer although there is good evidence that women 
screened for breast cancer have a better outcome than unscreened women
25
. All the GPs who screen for 
breast cancer recommend breast self-examinations although research has shown that breast self-examination 
does not reduce mortality and increases the number of unnecessary biopsies and therefore the harms out 
weigh the benefits
24
. All the GPs who screen do annual breast examinations. The varying strategies used by 
the GPs regarding mammography reflect the varying recommendations in the literature. However there is 
sufficient evidence that screening with mammography every 3 years from the age of 50 years, which is what 
most of the GPs are doing, reduces mortality
3
, is cost effective
26
 and the benefits outweigh the harms
5
. None 
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of the GPs who screen for breast cancer have a cut off age when they stop referring their patients for 
mammography despite there being no evidence that screening with mammography beyond the age of 70 
years is beneficial
3
. In keeping with evidence that breast cancer screening is more likely to benefit those at 
high risk
3
, the GPs screen these patients at a greater intensity. 
 
Despite recommendations that doctors should involve their patients in decisions about screening by 
discussing the balance between benefit and harm and the limitations of breast cancer screening
3
, none of the 
GPs does this with their patients. As has been shown in other research the GPs noted that disadvantaged 
patients tend to get breast cancer screening at a lower rate
23
.          
 
Screening for cervical cancer 
In keeping with recommendations all the GPs screen with for cervical cancer with PAP smears from the 
onset of sexual activity or about 20 years of age
3
. However some do not do PAP smears routinely at regular 
intervals as is recommended but rather erratically only when patients present with gynaecological problems 
or request PAP smears. Most of the GPs who do routine PAP smears do so annually although research shows 
that repeating PAP smears every three years is adequate
3
. Although there is limited evidence that screening 
women older than 65 years who have always had normal PAP smears is worthwhile
3
, most of the GPs screen 
throughout life. One GP includes a vaginal examination when doing PAP smears to screen for ovarian cancer 
despite there being no evidence to support this
70
. Research has shown that it is advisable to keep a register of 
patients who require PAP smears and sending reminders encourages women to have regular PAP smears
32
, 
but none of the GPs uses a register or recall system.      
  
Screening for colorectal cancer 
Only one GP screens for colorectal cancer which is in keeping with other research which has shown that 
screening rates for colorectal cancer are poor
44
. This is despite the fact there is good evidence that screening 
all men and women between the ages of 50 and 75 years reduces mortality from colon cancer
52
. The GPs feel 
patients find the screening tests like occult blood tests and colonoscopy unacceptable. However research has 
found that patients find faecal occult blood testing acceptable once the reasons for testing have been 
explained to them
46
. Patients do find the invasive procedures like sigmoidoscopy and colonoscopy less 
acceptable and may not be willing to undergo these for screening purposes
46
.   
  
Screening for hyperlipidaemia 
As is recommended all the GPs interviewed screen for hyperlipidaemia. However 5 of them only screen 
patients with risk factors for ischaemic heart disease, whereas they should be screening the general 
population
3
. Most of the GPs use a fasting lipogram to screen for hyperlipidaemia although a random non-
fasting cholesterol and HDL are adequate for initial screening. Only if the random cholesterol is elevated is it 
necessary to do the full fasting lipogram
55
. Most of the GPs are repeating lipograms annually even if these 
have previously been normal and the patient has no risk factors for ischemic heart disease, which is 
unnecessary, as it has been found reasonable to screen patients with normal lipograms every 5 years
3
. 
Although it is unnecessary, the GPs continue screening people over 65 years who have previously had 
normal tests
3
. 
 
Screening for prostate cancer 
Despite the fact that there is insufficient evidence to show that the benefits of screening for prostate cancer 
outweigh the harms
64
, most of the GPs interviewed screen for prostate cancer. Although screening is likely to 
benefit men between 50 and 75 years old the most, some of the GPs screen men as young as 40 years old and 
none have a cut off age when they stop screening. None of the GPs stops screening men with chronic medical 
illness and a life expectancy less than 10 years despite the fact these patients are unlikely to benefit from 
screening and treatment
3
. Despite the fact that screening every 4 years is as beneficial as screening annually
3
, 
almost all the GPs recommend their patients repeat PSA tests every year. Most of the GPs do not do digital 
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rectal examinations despite research showing that when combined with PSA these improve cancer detection 
rates
59
. Most of the GPs do not discuss the uncertainty regarding the benefit of prostate cancer screening with 
their patients so they are unable to make an informed choice of whether to screen or not.     
 
Screening for human immunodeficiency virus (HIV) infection 
The GPs interviewed are screening appropriately for HIV infection. The GPs are uncertain how often to 
repeat HIV tests and mostly leave this up to the patient which is appropriate as evidence is lacking on how 
frequently one should test.  Although the WHO recommends two separate HIV ELISA tests or rapid tests to 
confirm HIV infection
67
, most of the GPs only do one test. Only one GP uses rapid HIV tests routinely to 
screen for HIV although patients prefer rapid tests and they are now almost as accurate as the HIV ELISA 
test
68
. Most of the GPs do not do full HIV counselling and are not discussing potential harms of screening 
before doing the test but rather just stressing the benefits of knowing one’s HIV status. It is recommended 
that the patient makes an informed choice by being given counselling including information on potential 
benefits and harms
64
.  
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CONCLUSION 
 
The interviews have illustrated that because there are no protocols or guidelines for GPs in private practice 
they all have differing screening strategies and decide for themselves what to recommend to their patients 
based on different recommendations and old habits. The spectrum of screening strategies varies from the GP 
who is doing very little screening to those doing routine “executive” medical examinations where a full range 
of tests is done every year, both recommended and not recommended. Most of the GPs doing routine annual 
health checks are recommending additional tests not necessary for routine screening like homocysteine 
levels
71
, renal function tests
5
, liver function tests
5
, full blood counts
5
, lung function tests
3
 and stress ECGs
3
. 
Many of the GPs are pressurised by their patients to do screening tests they know are not worthwhile.  
 
General practitioners need to decide upon a general approach to prevention that will ensure that all their 
patients are screened according to evidence based recommendations. Routine annual health checks provide 
an ideal opportunity to carry out all recommended screening. General practitioners who choose to do routine 
annual check ups need to be aware that these can lead to doctors doing tests which are not recommended and 
ensure they only do those that are necessary. It is important for the GP to focus on the patients’ particular 
health risks while doing these routine health checks.  
 
It is not necessary to do routine annual health checks to complete recommended screening. But those general 
practitioners who choose not to do routine annual health checks should be aware that with this approach there 
is the risk they will not adequately screen all their patients. They need to be sure to provide time for 
prevention during consultations in order to detect tracer conditions and discuss preventive health issues. 
This constitutes a more opportunistic strategy to prevention and case finding. GPs can use both opportunistic 
and routine health check strategies to ensure recommended screening and prevention is done.     
 
A screening protocol is needed for GPs in private practice so that all doctors are making similar 
recommendations to their patients. A patient leaflet detailing necessary screening measures with a simple 
explanation about the benefits and harms of each will reduce patient confusion about what is necessary and 
assist GPs in helping patients make informed choices regarding screening.  
 
It is advisable for all GPs to keep check lists on each of their patients on what screening measures need to be 
done (see Addendum 3 for an example of a check list).  These check lists will need to be updated as 
recommendations change. It would be ideal for doctors to keep a register and recall system to ensure all 
screening measures are done on their patients. However my research has shown that this is not always 
possible in a busy general practice. It is therefore not unreasonable to leave it up to the patient to remember 
to attend for their screening measures. GPs need to be aware that disadvantaged patients often do not get 
screened adequately and make an effort to do what screening is possible for these patients. More research is 
needed to cover screening in neonates, children, pregnant women, adolescents, the elderly and including 
alcohol use, diabetes and hypertension in adults to formulate a comprehensive guideline for screening in 
general practice. 
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RECOMMENDATIONS 
 
Based on evidence in the literature and the information obtained from interviewing general practitioners in 
this research study the following are suggested pragmatic prevention strategies for the selected tracer 
conditions: 
 
Smoking cessation 
 GPs should screen all adolescents and adults for smoking whether they have a smoking related illness 
or not. 
 GPs should give smoking cessation advice to all those who smoke. They should try to spend as much 
time as possible and try to use motivational interviewing techniques when counselling patients to stop 
smoking. 
 GPs should follow up patients they counsel to stop smoking and offer a number of counselling 
sessions specifically related to smoking. 
 GPs should offer medication like bupropion or nicotine replacement therapy to smokers.  
 
Screening for breast cancer 
 GPs should screen women routinely for breast cancer but be aware of the limitations and potential 
harms of breast cancer screening and explain these to patients before they screen. 
 It is not necessary for GPs to recommend breast self-examinations but acceptable to teach those who 
request to learn how to do so. Patients must be informed about the potential harms and taught how to 
do it properly. 
 It is acceptable for GPs to perform annual breast examinations from the age of 30 years. 
 Considering cost and benefit versus harm it seems appropriate to screen with mammography women 
between the ages of 50 and 70 years every 3 years. 
 To reduce possible anxiety it is important to warn women before breast examinations and 
mammography that the majority of lumps detected turn out to be benign. 
 High risk patients like those with a family history, first child after 30 years or previous abnormal 
biopsy of a breast lump, should be screened more intensively, starting at a younger age and more 
frequently.  
 GPs must ensure their disadvantaged patients are screened at least with regular breast examination if 
they cannot afford mammography.  
 
Screening for cervical carcinoma 
 GPs should screen all women routinely for cervical cancer from within 3 years of the onset of sexual 
activity or 20 years of age, whichever comes first. 
 GPs should use PAP smears taken with a cytobrush and extended tip spatula to screen for cervical 
cancer. 
 High risk patients should be screened annually and low risk patients at least every 3 years. 
 High risk patients are those who have multiple sexual partners, HIV or HPV infections. If the GP is 
unable to be sure whether the patient has multiple sexual partners or is HIV positive or not, it is 
appropriate to screen annually as if the patient is high risk initially and extend the intervals between 
screenings once the GP is sure the patient is no longer high risk.   
 In women who have always had normal PAP smears, screening can be stopped after 65 years of age. 
 
Screening for colorectal cancer 
 GPs should screen all patients from the age of 50 to 75 years with annual faecal occult blood testing. 
 GPs should recommend sigmoidoscopy every 5 years and colonoscopy every 10 years on all patients 
from 50 years to 75 years of age.  
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 GPs should explain the reasons for testing to encourage patients to accept the screening measures. 
 GPs should refer patients at increased risk of colon cancer to specialists for more intensive screening.  
 Those at high risk are patients with a family history of colorectal cancer, familial polyposis and 
ulcerative colitis. 
 Those with a family history of colorectal cancer should start screening at age 40 years and where the 
relative developed the cancer younger than 50 years, 10 years before the age the family member 
developed the cancer.  
 
Screening for hyperlipidaemia 
 GPs should routinely screen all men from the age of 35 years and all women from the age of 45 years 
for hyperlipidaemia.  
 Random non-fasting cholesterol and HDL are adequate for initial screening. 
 A full fasting lipogram should be done if the random cholesterol is elevated. 
 If the patient has no risk factors for ischemic heart disease and a normal lipogram the GP only needs 
to repeat screening every 5 years.  
 Patients with no risk factors and normal lipograms do not need screening beyond 65 years of age. 
 Patients with risk factors for ischemic heart disease need to start screening at a younger age.  
 Patients with risk factors for ischemic heart disease or who take treatment for hyperlipidaemia need 
repeat lipograms annually. 
 Treatment should be offered to those at increased risk of coronary heart disease. 
 
Screening for prostate cancer 
 GPs need to be aware that there is insufficient evidence to show that the benefits of screening for 
prostate cancer outweigh the harms and point this out to their patients so that they can make an 
informed choice regarding screening. Patients need to know that the PSA and DRE can detect some 
cases of prostate cancer but there is no clear evidence that patients detected by screening have a better 
outcome than those detected when they present with symptoms. 
 If a patient chooses to be screened for prostate cancer a PSA test and DRE every 4 years between the 
ages of 50 and 75 years is appropriate. 
 GPs need to be aware that screening results in many false positive and false negative outcomes.  
 Prostate cancer screening in men over 75 years old or with chronic medical illness and a life 
expectancy less than 10 years is not recommended. 
 GPs need to be aware that it is unclear what the appropriate management is for patients detected by 
screening. 
 
Screening for human immunodeficiency virus (HIV) infection 
 GPs need to enquire about risk factors for HIV so they are aware who to screen. 
 GPs should consider screening all adolescents and young adults whether they have specific risk 
factors or not. 
 GPs should be aware that the potential harms of screening those not at risk could outweigh the 
benefits. Thus if the patient is certain they are not at risk HIV testing should not be done. 
 GPs should consider the prevalence of HIV infection in the population they serve when deciding who 
to screen. 
 High risk patients should be tested annually. 
 Low risk patients can repeat the test when they feel it is warranted. 
 GPs should consider doing rapid HIV tests to screen patients. 
 If the HIV rapid test is positive the GP should either repeat a second separate rapid test or do an 
ELISA to confirm the result. 
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 GPs should screen all pregnant women for HIV. 
 GPs should counsel patients including discussing potential benefits and harms before doing HIV tests 
so that patients can make an informed decision about whether to test or not.  
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ADDENDUM 1. Structured questionnaire for GP interviews 
 
PERIODIC HEALTH EXAMINATION / ROUTINE ANNUAL CHECK-UP 
 
Do you recommend routine medical examinations to your patients?  
 
If no:  
Why don’t you recommend routine medical examinations? 
When or how do you screen for preventative tracer conditions? 
 
If yes: 
From what age do you recommend these check-ups? 
How often do you recommend patients have routine health checks? 
How do you remember to carry out routine examinations? Do you keep a register or check list? 
What do you screen for in these health checks?   
What is your opinion on the value of these assessments? 
What illnesses do you detect during these examinations? 
Do you focus interventions on the individual’s particular health practices or do you have a standard screening 
strategy? 
Do you discuss preventative health issues during this examination and if so which? 
Do patients demand routine health examinations?  
Do you involve your patients in decisions about routine examinations by discussing potential benefits, harms 
and implications?  
Do you feel the cost is justified? 
Do periodic health examinations improve your relationship with your patient? 
Do your more disadvantaged patients tend to get this preventive service at a lower rate? 
What obstacles or barriers do you encounter doing these examinations? (Doctor/patient/health system) 
 
SMOKING CESSATION 
 
Do you screen your patients for smoking? 
 
If no: 
Why don’t you screen for smoking? 
 
If yes: 
What strategy do you use to screen for smoking? 
(When and how do you screen for smoking?) 
 
Do you offer counselling for smoking cessation and if so what strategy do you use? 
(Do you use motivational interviewing to encourage smoking cessation?) 
Do you tend to give smoking cessation advice only or mainly when the patient presents with a smoking 
related problem? 
How long do you spend on smoking cessation advice? 
Do you advise patients to use nicotine replacement therapy or bupropion to help with smoking cessation?  
Do you follow up patients you counsel for smoking cessation? If so how many sessions do you have with 
them? 
Do you feel smoking cessation interventions are effective? 
Do you find it difficult to remember to screen for smoking? Do you use a check list to remind you? 
What are your views on and experiences of screening and counselling for smoking? 
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(Do you encounter any obstacles or barriers to screening and counselling for smoking?) 
Do you feel patients in general lack motivation to stop smoking? 
Do you find discussions about smoking unpleasant? 
Do you find them too time consuming? 
 
SCREENING FOR BREAST CARCINOMA 
 
Do you screen for breast cancer? 
 
If no: 
Why don’t you screen for breast cancer? 
 
If yes:  
What screening strategy do you use for breast cancer?  
Do you teach your patients and recommend they do routine breast self examinations? 
Do you do routine clinical breast examinations? 
Do you refer patients for mammography? 
What age do you start breast cancer screening/mammography?  
What ages do you stop breast cancer screening/ mammography? 
How frequently do you screen for breast cancer? 
Do you keep a check list or register? 
Do you involve your patients in decisions about screening? 
Do you discuss potential benefits, limitations, and possible harms of mammography with patients before 
referring for the procedure? 
Do your patients find the screening measures of breast cancer acceptable? 
What are your views on and experiences of screening for breast cancer? 
Do you encounter any obstacles to screening for breast cancer? (Doctor / patient / health system)  
Do your more disadvantaged patients tend to get screened for breast cancer at a lower rate? 
 
SCREENING FOR CERVICAL CARCINOMA 
 
Do you screen for cervical cancer? 
 
If no: 
Why don’t you screen for cervical cancer? 
 
If yes: 
What screening strategy do you use for detecting cervical carcinoma? 
    What screening measure/s do you use? 
    At what age do you recommend women start doing PAP smears? 
    How often do you recommend patients repeat PAP smears if their results are normal? 
    At what age do you recommend women stop doing PAP smears? 
 
Do you involve your patients in decisions about screening? 
Do you do the PAP smears or does a nursing sister do them? 
What device do you use for obtaining specimens? 
Do you use liquid based cytology or smear technology? Why? 
Do you do HPV tests as part of screening for cervical carcinoma? 
Do you keep a register or use patient reminders? 
Who do you regard high risk and how often do you screen them? 
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Do your patients find PAP smears acceptable? 
Do your female patients avoid or delay having PAP smears? 
Do you encounter any obstacles screening for cervical carcinoma? 
What are your views on and experiences of screening for cervical carcinoma? 
 
SCREENING FOR COLORECTAL CANCER 
 
Do you screen for colorectal cancer? 
 
If no: 
Why don’t you screen for colorectal cancer? 
 
If yes: 
What screening strategy do you use? 
What tests do you recommend? 
From what age do you recommend patients undergo these tests? Until what age? 
How often do you recommend they have these screening tests? 
 
Who do you consider high risk patients and what screening strategy do you recommend for these patients? 
Do you have a register and recall system? 
Do you sometimes forget to offer screening? 
Would you consider your screening rate high or low? 
Are patients reluctant to undergo screening tests? 
Do you involve your patients in decisions about screening? 
What are your views on and experiences of colorectal cancer screening? 
Do you encounter any obstacles screening for colorectal cancer? 
Do people from lower socio-economic communities get screened less? 
 
SCREENING FOR HYPERLIPIDAEMIA 
 
Do you screen for hyperlipidaemia? 
 
If no: 
Why don’t you screen for hyperlipaemia? 
 
If yes: 
What screening strategy do you use for hyperlipidaemia? 
 
Which tests do you use? 
At what age do you start and until what age do you recommend screening for hyperlipidaemia? 
What interval do you recommend between screenings for those not at risk with normal results / those at risk/ 
those with abnormal results? 
Do you keep a register or have a recall system? 
Do your patients find the treatment of hyperlipidaemia acceptable? 
Do you discuss the advantages and disadvantages of screening and treatment?  
What are your views on and experiences of screening for hyperlipidaemia? 
Do you encounter any obstacles screening for hyperlipidaemia? 
Do you feel patients generally are reluctant to heed advice regarding leading healthy lifestyles? 
Do your more disadvantaged patients tend to screen for hyperlipidaemia at a lower rate? 
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SCREENING FOR HUMAN IMMUNODEFICIENCY VIRUS INFECTION 
 
Do you screen for HIV infection? 
If no: 
Why don’t you screen for HIV infection? 
 
If yes: 
What strategy do you use to screen for HIV infection? 
 
Do you routinely screen all adolescents and adults or only those at increased risk? 
If you only screen those at increased risk what factors do you consider increased risk? 
How do you assess for risk? 
Do you consider the prevalence of HIV infection or the risk characteristics of the population when 
determining a screening strategy? 
How frequent do you recommend HIV tests? 
What tests do you use to screen for HIV infection? 
Do you keep a check list or register? 
Do you screen all pregnant women for HIV? 
Do you do the tests as part of antenatal blood tests without specifically getting consent? 
Do those at risk find the screening measure and/or treatment acceptable? 
Do you discuss potential benefits and harms of HIV testing? 
Do you involve your patients in decisions about screening? 
What barriers or obstacles do you experience in carrying out screening? (Doctor/ patient/ health system) 
 
SCREENING FOR PROSTATE CANCER 
 
Do you screen for cancer of the prostate? 
If no: 
Why don’t you screen for prostate cancer? 
If yes: 
What screening strategy do you use? 
 
What age do you recommend starting screening for prostate cancer?  
Up until which age do you screen for prostate cancer? 
Do you exclude any patients from screening? 
How frequently do you recommend testing? 
What tests do you recommend? 
Do you keep a check list or register? 
Do you involve your patients in decisions about screening? / Do you discuss the benefits and harms of 
screening and treatment before making recommendations? 
What barriers or obstacles do you experience in carrying out screening? ( Doctor/ patient/ health system) 
Do those at risk find the screening measures and treatment of prostate cancer acceptable? 
Do your more disadvantaged patients tend to screen for prostate cancer at a lower rate? 
 
GENERAL QUESTIONS 
 
Do you find you have time to carry out recommended screening? 
Do you feel confident about which screening measures to recommend? 
Do you tend to recommend well established traditional screening measures? 
Do you use newly recommended screening measures? 
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Do you discuss prevention at every consultation? If not when do you discuss prevention? 
Do you find it too time consuming to explain the evidence regarding a given screening procedure? 
Do you get pressurised by patients to carry out a preventive measure that is not worthwhile? Which? 
 
CONCLUSION 
 
Do you have anything you would like to add regarding the prevention strategy you use for the above 
preventive measures? 
Do you have anything you would like to add about preventive strategies in general? 
Thank you for your participation in my research. 
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ADDENDUM 2. Informed consent to conduct interviews 
 
PARTICIPANT INFORMATION LEAFLET AND CONSENT FORM  
 
TITLE OF THE RESEARCH PROJECT: Evaluating prevention strategies used by general practitioners in 
terms of recommended guidelines. 
 
REFERENCE NUMBER: N08/06167 
PRINICIPAL INVESTIGATOR: Dr M.D.Godlonton 
ADDRESS: 41 Hill Street Grahamstown 
CONTACT NUMBER: 0828515480 
 
You are being invited to take part in a research project. Please take some time to read the information 
presented here, which will explain the details of this project. Please ask the study doctor any questions about 
any part of this project that you do not fully understand. It is very important that you are fully satisfied that 
you clearly understand what this research entails and how you could be involved. Also, your participation is 
entirely voluntary and you are free to decline to participate. If you say no, this will not affect you negatively 
in any way whatsoever. You are also free to withdraw from the study at any point, even if you do agree to 
take part.  
 
This study has been approved by the Committee for Human Research at Stellenbosch University and will be 
conducted according to the ethical guidelines and principles of the international Declaration of Helsinki, 
South African Guidelines for Good Clinical Practice and the Medical Research Council (MRC) Ethical 
Guidelines for Research.  
 
What is this research study all about?  
This study will be conducted in Grahamstown. All general practitioners in private practice in Grahamstown 
will be invited to participate in the study.  
The aim of the study is to evaluate the prevention strategies used by general practitioners (GPs) in 
Grahamstown in terms of the recommended guidelines for appropriate tracer conditions. By tracer conditions 
I mean diseases which can be detected and treated early by screening measures or prevention strategies, 
rather than wait for presentation later when there are obvious symptoms or signs. I am doing the study 
because prevention is an important part of family practice but constraints on consultation time and medical 
funds makes it difficult to be sure which measures are appropriate and when to carry them out. I want to find 
out what prevention strategies GPs in Grahamstown practice and their views and obstacles experienced 
carrying these out. I then want to compare the prevention strategies used by GPs with recommended 
guidelines. Finally I hope to use all this information to make recommendations for successful screening in 
general practice in Grahamstown. 
 
I have invited you as a general practitioner in private practice to participate because your views and approach 
to preventive measures and obstacles you experience carrying them out are very important to this study. This 
information will help to identify important issues on preventive screening in private practice.  
 
What will your responsibilities be?  
I will make an appointment with you to conduct an interview which will last about an hour. In the interview I 
will you ask you about the preventive strategies for certain tracer conditions you use in your clinical practice 
and your views and obstacles you experience regarding these preventive measures. I would like to record the 
interviews. If you feel uncomfortable being recorded I can make written notes on your responses.    
 
Will you benefit from taking part in this research?  
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You may benefit from the exercise of analysing the preventive strategy you use in your practice. Hopefully 
the research will help general practitioners in private practice improve their screening strategies for their 
patients.  
  
Who will have access to your interviews?  
Only I will have access to your interviews. I will conduct all the interviews and transcribe the recordings for 
analysis. No names will be linked to the data and interviews will be destroyed after analysis. All information 
you give me will be treated as confidential and will be protected. Reporting on data will be done 
anonymously. Data will be analysed qualitatively. Themes or patterns of practice and similar ideas or 
obstacles will be grouped together. Thus once analysed for reporting data will not resemble the original 
interviews and not be linked to individuals. 
   
Is there any thing else that you should know or do?  
You can contact the Committee for Human Research at 021-938 9207 if you have any concerns or 
complaints that have not been adequately addressed by your study doctor.  
You will receive a copy of this information and consent form for your own records.  
 
By Signing below, 
 
 I…………………………………………………………………… agree to take part in a research study 
entitled: Evaluating prevention strategies used by general practitioners in terms of recommended guidelines.   
 
I declare that:  
· I have read or had read to me this information and consent form and it is written in a language with which I 
am fluent and comfortable.  
· I have had a chance to ask questions and all my questions have been adequately answered.  
· I understand that taking part in this study is voluntary and I have not been pressurised to take part.  
· I may choose to leave the study at any time and will not be penalised or prejudiced in any way.  
· I may be asked to leave the study before it has finished, if the study doctor or researcher feels it is in my 
best interests, or if I do not follow the study plan, as agreed to.  
 
 
Signed at ………………………… …………….on ……………………………….... 2009  
 
 
………………………… .. ………………………                                
………………………………………………….. 
Signature of Participant                                                                          Signature of witness 
 
Declaration by Investigator  
I ………………………………………………………….. declare that:-  
· I explained the information in this document to ……………………………………....  
· I encouraged him/her to ask questions and took adequate time to answer them.  
· I am satisfied that he/she adequately understands all aspects of the research, as discussed above  
· I did not use a translator. 
  
Signed at ……………………………………….on ………………………………….2009  
 
………………………… .. ………………………        …………………………………………………. 
Signature of Investigator                                                                         Signature of Witness.  
Stellenbosch University  https://scholar.sun.ac.za
 47 
ADDENDUM 3. Check list for adult screening 
 
HISTORY 
 
1. Diet and weight loss counselling if necessary 
2. Exercise 
3. Sun exposure education 
4. Safe sex and STD education 
5. Females of childbearing age: folic acid 
6. Family history of illness 
 
HABITS 
 
1. Smoking –yes or no  
If yes:  
 smoking cessation advice/counselling 
 nicotine replacement or bupropion 
 follow up 
 
2. Alcohol –yes or no 
If yes: 
 case finding for problem drinking 
 counselling for problem drinking   
 
PHYSICAL EXAMINATION 
 
Full physical examination including waste circumference, hip / waste ratio, weight, height and BMI 
 
SPECIAL INVESTIGATIONS 
 
Random cholesterol or fasting lipogram (men >35 years / women >40 years or younger if at risk)  
 Repeat annually if other risk factors 
 Repeat every 5 years if no other risk factors 
 
Fasting glucose (men >35 years / women >40 years or younger if at risk) 
 Repeat annually if at risk 
 Repeat every 5 years if no risk 
 
HIV test  
 Repeat annually if high risk 
 
Colorectal cancer (50 to 75 years) 
 Stool occult blood annually 
 Sigmoidoscopy every 5 years 
 Colonoscopy every 10 years 
 Refer high risk for intensive screening 
 
Cervical cancer (female sexually active or 20 to 65 years) 
 PAP smear annual if high risk 
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 PAP smear every 3 years if low risk and previously normal  
 
Breast cancer (female 50 to 70 years) 
 Breast examination annual 
 Mammogram every 3 years  
 
Prostate cancer (men 50 to 75 years) 
 PSA and DRE every 4 years 
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